University of Kentucky

UKnowledge
Neuroscience Faculty Patents

Neuroscience

2-3-2015

Method of Treating Parkinson's Disease in Humans by
Convection-Enhanced Infusion of Glial Cell-Line Derived
Neurotrophic Factor to the Putamen
Stephen S. Gill
Don M. Gash
University of Kentucky, dongash@email.uky.edu

Greg A. Gerhardt
University of Kentucky, gregg@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/neurobio_patents
Part of the Medical Anatomy Commons, and the Medical Neurobiology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Gill, Stephen S.; Gash, Don M.; and Gerhardt, Greg A., "Method of Treating Parkinson's Disease in Humans
by Convection-Enhanced Infusion of Glial Cell-Line Derived Neurotrophic Factor to the Putamen" (2015).
Neuroscience Faculty Patents. 7.
https://uknowledge.uky.edu/neurobio_patents/7

This Patent is brought to you for free and open access by the Neuroscience at UKnowledge. It has been accepted
for inclusion in Neuroscience Faculty Patents by an authorized administrator of UKnowledge. For more information,
please contact UKnowledge@lsv.uky.edu.

USOO8946151B2

(12) Unlted States Patent

(10) Patent N0.2

Gill et a].
(54)

(45) Date of Patent:

METHOD OF TREATING PARKINSON’S

5,731,284 A

3/1998 Williams

5,752,930 A

5; 1998 Rise

2 ,,

GLIAL CELL-LINE DERIVED

6,042,549 A

NEUROTROPHIC FACTOR TO THE

6,093,180 A

7/2000 Elsberry

6,093,802 A
6,184,200 B1

7/2000 Lin
2/2001 Hu

.

-

~

.

6,309,634 B1 *

Ef?gy; 1:1“

3

3

3

6,319,241 B1

‘

Gerhardt, Nicholasville, KY (US)
Assignees: Northern Bristol N.H.S. Trust

<69;

( * ) Notice:

6,362,319 B1

3/2002

4/2003 Elsberry

6,589,205 B1

7/2003 Meadows

6592571 B1

7/2003 V?lrbeek et ?l~

Lin et al.

2322231215; 10/2001
2222; am
Elsberrt

Foundatlon, LeXlngIOH, KY (US);

2002/0187127 A1* 12/2002 Bankiewicz ............... .. 424/93.2

Amgen Inc., Thousand Oaks, CA (US)

2003/0120262 A1

6/2003 Wieland
10/2003

Lee _

glorng

.

ur

e

patent Is extended or adjusted under 35

2003/0216700 A1

11/2003 Pearson

U-S-C- 154(1)) by 1083 days-

2003/0216714 A1

11/2003 Gill

This

2003/0225372 A1

12/2003 Christenson

_

atent is sub-em to a tenninal dis_
P

J

2005/0119712 A1

6/2005

2005/0123526 A1

6/2005 Shafer

(21) Appl- NO-I 10/9631986

Prior Publication Data

Us 2005/0137134 A1

W0

WO 93/06116

4/1993

W0

WO 02/07810

1/2002

W0

W0 03/002170

10003

Jun. 23, 2005

(Commued)
OTHER PUBLICATIONS

Related US. Application Data

(63) Continuati0n_in_pan of application NO' 10/784’547’
?led on Feb 23 2004
'

’

Shafer

FOREIGN PATENT DOCUMENTS

Oct. 13, 2004

(65)

MIckle Iet a1. Genotype-phenotype relat10nsh1p*s 1n cystIc ?br0s1s.
Med ClIn North Am. May 2000;84(3):597-607.

'

Voet et al. Biochemistry. 1990. John Wiley& Sons, Inc. 126-129 and

Provisional application No. 60/449,789, ?led on Feb.

228-234?“

24, 2003_

Yan et al. Two-amino acid molecular switch in an epithelial

Int_C1_

morphogen that regulates binding to two distinct receptors. Science
290; 523-527, 2000*

A61K 38/18

(200601)

' '

Yurek. Glial cell-line-derived neurotrophic factor improves survival
0 fd opam1nerglc

USCI

CPC

'

A61K38/185 (2013 01)

neurons

lIl

tr3115p1 ant S

0 fftal
e

ven trl
a

mesence halic tissue. EX Neurol. Oct. 1998;153 2 :195-202.*

p

p

USPC ........................... .. 514/83; 514/84; 514/177

(58)

...... .. 424/932

2001/002/599 A1

Clalmer-

(52)

Bankiewicz et al.

UniVeYSiFY 0f Kentucky Research

.

(51)

10/2001

11/2001 King

Subject to any disclaimer, the term of this

Filed:

435/71

6,551,290 B1

2003/0199829 A1

(60)

gfflltal
3/2000 Amano et a1.

PUTAMEN

(75) Inventors

(22)

*Feb. 3, 2015

DISEASE IN HUMANS BY

CONVECTION-ENHANCED INFUSION OF

(73)

US 8,946,151 B2

< )

(Commued)

Field of Classi?cation Search
None

See application ?le for complete search history.

(56)

References Cited
US. PATENT DOCUMENTS
3,923,060 A
4,003,379 A

12/1975 Ellinwood
1/1977 Ellinwood

P '

E

'

G

s E

11

nmary xamlner i regory
me
_
(74) Attorney, Agent, or Fzrm * Marshall, Gerstem& Borun

LLP

(57)

ABSTRACT

A method of treating Parkinson’s disease in humans is dis

4,013,074 A

3/1977 Siposs

closed, wherein glial cell-line derive neurotrophic factor

4,146,029 A
4,447,224 A
4,588,394 A

3/1979 Ellinwood
5/1984 DeCant
5/1986 Schulte

putamen of a human in need of treatment thereof via convec

4,692,147 A

9/1987 Duggan

4,714,462 A
4,838,887 A
4,931,050 A

12/1987 DiDomenic
6/1989 Idriss
6/1990 Idriss

4,978,338 A

12/1990 Melsky

5,176,641 A
5,207,666 A

1/1993 Idriss
5/1993 Idriss

5,575,770 A

11/1996 Melsky

5,643,207 A
5,720,720 A

7/1997 Rise
2/1998 Laske

(GDNF) is chronically administered directly to one or both

tion-enhanced infusion using at least one implantable pump
and at least one catheter. In one aspect of the present invention
the GDNF is infused directly into one or both putamen

through one or more indwelling intraparenchymal multiport
brain catheters connected to one or more implantable pumps

wherein the ?ow rate is pulsed.

43 Claims, 5 Drawing Sheets

US 8,946,151 B2
Page 2
(56)

References Cited
FOREIGN PATENT DOCUMENTS

W0
W0
W0
W0
W0

W0 03/007785
W0 03/077785
W0 03/090689 A2
WO 2004/075720 A2
WO 2005/120548 A1

1/2003
9/2003
11/2003
9/2004
12/2005

OTHER PUBLICATIONS

Maswood et al., “Effects of chronic intraputamenal infusion of Glial
cell line-derived neurotrophic factor (GDNF) in aged Rhesus mon

keys,” Neurobiology onging 23:881-889 (2002).
Olson et al., “Nerve growth factor affects llC-nicotine binding, blood
?ow, EEG, and verbal episodic memory in an Alzheimer patient,” J
Neural Transm. 4:79-95 (1992).
Olson et al., “Intraputaminal Infusion of nerve growth factor to sup

port adrenal medullary autografts in Parkinson’s disease,” Arch.
Neurol. 48:373-381 (1991).
Rosenblad et al., “Intrastriatal glial cell line-derived neurotrophic

factor promotes sprouting of spared nigrostriatal dopaminergic
afferents and induces recovery of function in a rat model of

Ai et al., “Intraputamenal infusion of GDNF in aged rhesus monkeys:
distribution and dopaminergic effects,” J Comp. Neurol. 461:250
261 (2003).
Bj orklund et al., “Towards a neuroprotective gene therapy for
Parkinson’s disease: use of adenovirus, AAV and lentivirus vectors
for gene transfer of GDNF to the nigrostriatal system in the rat

Parkinson model,” Brain Research 886:82-98 (2000).
Bj orklund et al., “Parkinson disease gene therapy moves toward the
clinic,” Nature Med. 6: 1207-1208 (2000).
Bowenkamp et al., “6-hydroxydopamine induces the loss of the
dopaminergic phenotype in substantia nigra neurons of the rat: a

possible mechanism for restoration of the nigrostriatal circuit medi

ated by glial cell line-derived neurotrophic factor,” Exp. Brain Res.
111:1-7 (1996).
Choi-Lundberg et al., “Dopaminergic neurons protected from degen
eration by GDNF gene therapy,” Science 275:838-841 (1997).

Parkinson’s disease,” Neuroscience 82: 129-137 (1998).
Shults et al., “Intrastriatal injection of GDNF attenuates the effects of

6-hydroxydopamine,” NeuroReport, 7:627-631 (1996).
Tomac et al., “Protection and repair of the nigro striatal dopaminergic
system by GDNF in vivo,” Nature 373:335-339 (1995).
Tomac et al., “Retrograde axonal transport of glial cell line-derived
neurotrophic factor in the adult nigrostriatal system suggests a
trophic role in the adult,” Proc. Natl. Acad Sci. (USA), 92:8274-8278

(1995).
Wenning et al., “Short- and long-term survival and function of uni

lateral intrastriatal dopaminergic grafts in Parkinson’s disease,”Ann.
Neurol. 42: 95-107 (1997).
Zhang et al., “Dose response to intraventricular glial cell line-derived
neurotrophic factor administration in Parkinsonian monkeys,” J
Pharmacol. Exp. Ther. 282:1396-1401 (1997).
International Search Report for International Application No. PCT/

US2004/005063 (Sep. 7, 2004).

Connor et al., “Differential effects of glial cell line-derived

Gill et al., “Intraparenchyrnal putaminal administration of glial-de

neurotrophic factor (GDNF) in the striatum and substantia nigra of
the aged Parkinsonian rat,” Gene Therapy 6: 1936-1951 (1999).
Gash et al., “Functional recovery in parkinsonian monkeys treated
with GDNF,” Nature 380:252-255 (1996).
Gash et al., “Neuroprotective and neurorestorative properties of
GDNF,” Ann. Neurol. 44:S121-S125 (1998).
Grondin et al., “Chronic intracerebral delivery of trophic factors via

rived neurotrophic factor in the treatment of advanced Parkinson’s

a programmable pump as a treatment for Parkinsonism,” Methods in

Molecular Medicine 62:257-267 (2001).
Grondin et al., “Chronic, controlled GDNF infusion promotes struc
tural and functional recovery in advanced parkinsonian monkeys,”
Brain 125:2191-2201 (2002).
Grondin et al., “Glial cell line-derived neurotrophic factor increases
stimulus-evoked dopamine release and motor speed in aged rhesus
monkeys,” J Neurosci. 23:1974-1980 (2003).
Hou et al., “Glial cell line-derived neurotrophic factor exerts
neurotrophic effects on dopaminergic neurons in vitro and promotes

their survival and regrowth after damage by 1-methy1-4
phenylpyridinium,” J Neurochem. 66:74-82 (1996).
Kearns et al., “GDNF protects nigral dopamine neurons against
6-hydroxydopamine in vivo,” Brain Research 672: 104-1 11 (1995).
Kirik et al., “Long-term rAAV-mediated gene transfer of GDNF in
the rat Parkinson’s model: intrastriatal but not intranigral transduc

disease,” Neurology A241 :58 (2002).
Brundin, “GDNF treatment in Parkinson’s disease: Time for con

trolled clinical trials?,” Brain 125:2149-2151 (2002).
Grondin et al., “Glial cell line-derived neurotrophic factor (GDNF):
A drug candidate for the treatment of Parkinson’s disease,” J Neurol

245:P35-P42 (1998).
Ai et al., “Intraputamenal infusion of GDNF in aging rhesus mon

keys: Distribution and dopaminergic effects,” J Comp. Neurol.
461 1250-61 (2003).
Atkinson, “Three standard errors of measurement and the Wechsler

memory scaleirevised,” Psychological Assessment 3:136 -138

(1991).
Barbeito et al., “Activation of the bilateral corticostriatal

glutamatergic projection by infusion of GABA into thalamic motor
nuclei in the cat: An in vivo release study,” Neuroscience 28:365-374

(1989).
Beck et al., “Mesencephalic dopaminergic neurons protected by
GDNF from axotomy-induced degeneration in the adult brain,”
Nature 373:339-341 (1995).
Bobo et al., “Convection-enhanced delivery of macromolecules in
the brain,” Proc. Nat. Acad. Sci. USA. 91:2076-2080 (1994).
Brett et al., “Region of interest analysis using an SPM toolbox,”

Kirik et al., “Localized striatal delivery of GDNF as a treatment for

abstract, NeuroImage 16 (2002).
Brooks et al., “Differing patterns of striatal 18F-dopa uptake in
Parkinson’s disease, multiple system atrophy, and progressive
supranuclear palsy,”Ann. Neurol. 28:547-555 (1990).
Brooks, “The relationship between locomotor disability, autonomic
dysfunction, and the integrity of the striatal dopaminergic system in
patients with multiple system atrophy, pure autonomic failure, and

Parkinson Disease,” Nature Neuroscience 7: 105-110 (2004).

Parkinson’ s disease, studied with PET,” Brain, 113 (Pt 5) 1539-1552

tion promotes functional regeneration in the lesioned nigrostriatal
system,” J Neurosci. 20:4686-4700 (2000).
Kirik et al., Delayed infusion of GDNF promotes recovery of motor
function in the partial lesion model of Parkinson’s disease, Eur. J
Neuroscience 13:1589-1599 (2001).

Kordower et al., “Neurodegeneration prevented by lentiviral vector

(1990).

delivery of GDNF in primate models of Parkinson’ s disease,” Science

Chen et al., “Variables affecting convection-enhanced delivery to the
striatum: a systematic examination of rate of infusion, cannula size,
Infusate Concentration, and Tissue-Cannula Sealing Time,” J

290:767-773 (2000).
Lindvall et al., “Clinical observations after neural transplantation in
Parkinson’s disease,” Prog. Brain Res. 127:299-320 (2000).
Lin et al., “GDNF: a glial cell-line derived neurotrophic factor for
midbrain dopaminergic neurons,” Science 260: 1130-1 132 (1993).
Lin et al., “Puri?cation and initial characterization of rat B49 glial
cell line-derived neurotrophic factor,” J Neurochem. 63:758-768

(1994).
Ma et al., “Dyskinesia after fetal cell transplantation for
Parkinsonism: a PET study,”Ann. Neurol. 52:628-634 (2002).

Neurosurg. 90:315-20 (1999).
Daniel et al., “Preliminary diagnosis of Parkinson’s disease by olfac
tory bulb pathology,” Lancet 340: 186 (1992).
Defer et al., “Core assessment program for surgical interventional

therapies in Parkinson’s disease (CAPSIT-PD),” Mov. Disord.
14:572-584 (1999).
Freed et al., “Transplantation of embryonic dopamine neurons for
severe Parkinson’s disease,” N. Engl. J Med. 344:710-719 (2001).

US 8,946,151 B2
Page 3
(56)

Olanow et al., “A double-blind controlled trial of bilateral fetal nigral
transplantation in Parkinson’s disease,” Ann. Neurol. 54:403-414

References Cited
OTHER PUBLICATIONS

(2003).
Otsuka et al., “Differences in the reduced 18F-Dopa uptakes of the

Garnett, “Dopamine visualized in the basal ganglia of living man,”
Nature 305: 137-138 (1983).
Gill et al., Direct brain infusion of glial cell line-derived neurotrophic
factor in Parkinson disease, Nat. Med 9:589-595 (2003).
Glowinski et al., “Role of the thalamus in the bilateral regulation of
dopaminergic and GABAergic neurons in the basal ganglia,” Ciba

Found Symp. Pitrnan, London, 107: 150-163 (1984).
Grondin et al., “Glial cell line-derived neurotrophic factor increases
stimulus-evoked dopamine release and motor speed in aged rhesus

monkeys,” J Neurosci., 23:1974-1980 (2003).
Hagell, “Dyskinesias following neural transplantation in Parkinson’s
disease,” Nat. Neurosci. 5:627-628 (2002).
Hamilton et al., “Heparin coinfusion during convection-enhanced
delivery (CED) increases the distribution of the glial-derived
neurotrophic factor (GDNF) ligand family in rat striatum and
enhances the pharmacological activity of neurturin,” Exp. Neurol.
168:155-61 (2001).
Hebert et al., “Behavioral and neurochemical effects of intranigral
administration of glial cell line-derived neurotrophic factor on aged
Fischer 344 rats,” J Pharm. Exp. 282:760-768 (1997).
Hebert et al., “Functional effects of GDNF in normal rat striatum:

Presynaptic studies using in vivo electrochemistry
microdialysis,” J Pharm. Exp. Ther. 279: 1181-1 190 (1996).

and

Hoffman et al., “In vivo microdialysis studies on somatodendritic
dopamine release in the rat substantia nigra: Effects of unilateral

caudate and the putamen in Parkinson’s disease: Correlations with
the three main symptoms,” J Neurol. Sci. 136:169-173 (1996).
Pahwa et al., “High-frequency stimulation of the globus pallidus for
the treatment of Parkinson’s disease,” Neurology 49:249-253 (1997).

Pal? et al., “Lentivirally delivered glial cell line-derived neurotrophic
factor increases the number of striatal dopaminergic neurons in pri
mate models of nigrostriatal degeneration,” J Neurosci. 22:4942

4954 (2002).
Pate et al., “Correlation of striatal ?uorodopa uptake in the MPTP
monkey with dopaminergic indices,” Ann. Neurol. 34:331-338

(1993).
Patlak et al., “Graphical evaluation of blood-to-brain transfer con

stants from multiple-time uptake data. Generalizations,” J Cereb.
Blood Flow Metab. 5:584-590 (1985).
Peto et al., “The development and validation of a short measure of

functioning and well being for individuals with Parkinson’s disease,”

Qual. Life Res. 4:24l-248 (1995).
Quinn et al., “Olfactory threshold in Parkinson’ s disease,” J Neurol.

Neurosurg. Psychiatry 50:88-89 (1987).
Rakshi et al., “Frontal, midbrain and striatal dopaminergic function
in early and advanced Parkinson’s disease A 3D [18F]dopa-PET

study,” Brain 122:1637-1650 (1999).
Rascol et al., “Limitations of current Parkinson’s disease therapy,”

Ann. Neurol. 53 (Suppl 3):S3-15 (2003).

6-OHDA lesions and GDNF,” Exp. Neurol. l47:l30-l4l (1997).

Romrell et al., “Rationale for current therapies in Parkinson’s dis

Holm, “A simple sequentially rejective multiple test procedure,”

ease,” Expert Opin. Pharmacother. 4: 1747-1761 (2003).
“The Deep-Brain Stimulation for Parkinson’s Disease Study Group,”
N. Engl. J. Med. 345:956-963 (2001).
Wenning et al., “Short- and long-term survival and function of uni
lateral intrastriatal dopaminergic grafts in Parkinson’s disease,”Ann.
Neurol. 42:95-107 (1997).
Whone et al., “The REAL-PET study: Slower progression in early
Parkinson’s disease treated with ropinirole compared with L-dopa,”

Scand J Statist. 6:65-70 (1979).

Hughes et al., “What features improve the accuracy of clinical diag

nosis in Parkinson’s disease: A clinicopathologic study,” Neurology
42: 1142-1 146 (1992).

Kordower et

al.,

“Clinicopathological

?ndings

following

intraventricular glial-derived neurotrophic factor treatment in a

patient with Parkinson’s disease,” Ann Neurol. 46:419-424 (1999).
Krack et al., “Five-year follow-up of bilateral stimulation of the
subthalamic nucleus in advanced Parkinson’s disease,” N. Engl. J
Med 349:1925-1934 (2003).
Langston et al., “Core assessment program for intracerebral trans

plantations (CAPIT),” Mov. Disord. 7:2-l3 (1992).
Lieberman et al., “Convection-enhanced distribution of large mol
ecules in gray matter during interstitial drug infusion,” J Neurosurg.
82: 1021-1029 (1995).
Martin et al., “Nigrostriatal function in humans studied with positron

emission tomography,”Ann. ofNeurol. 26:535-542 (1989).

Neurology 58 (Suppl 3): A82-A83 (2002).
International Search Report, PCT/US2005/034347, Apr. 19, 2007.
Bobo et al., “Convention-enhanced delivery of macromolecules in
the brain,” Proc. Natl. Acad. Sci. USA 91:2076-2080 (1994).
Gill et al. “Direct brain infusion of glial cell line-derived neurotrophic
factor in parkinson disease,” Nature Medicine 9:589-595 (2003).
Hamilton et al. “Heparin coinfusion during convection-enhanced

delivery (CED) increases the distribution of the glial-derived
neurotrophic factor (GDNF) ligand family in rat striatum and
enhances the pharmacological activity of neurturin,” Experimental

McCaIter et al., “Cognitive functioning after subthalamic
nucleotomy for refractory Parkinson’s disease,” J Neurol.

Neurology 168:155-161 (2001).

Neurosurg. Psychiatry 69:60-66 (2000).

with parkinson disease through the unilateral intraputaminal infusion
of glial cell line-derived neurotrophic factor,”J. Neurosurg 102:216
222 (2005).
Amgen press release, “Following Complete Review of Phase 2 Trial
Data Amgen Con?rms Decision to Halt GDNF Study; Comprehen
sive Review of Scienti?c Findings, Patient Safety, Drove Decision,”

Miyoshi et al., “Glial cell line-derived neurotrophic factor-levodopa
interactions and reduction of side effects in Parkinsonian monkeys,”
Ann. Neurol. 42:208-214 (1997).
Morrish et al., “An [18F]dopa-PET and clinical study of the rate of
progression in Parkinson’s disease,” Brain: 585-591 (1996).
Morrish et al., “Measuring the rate of progression and estimating the

preclinical period of Parkinson’s disease with [18F]dopa PET,”
Neurol., Neurosurg. & Psychiatry 64:314-319 (1998).
Nguyen et al., “Convective distribution of macromolecules in the

Slevin et al. “Improvement of bilateral motor functions in patients

as published on the internet Feb. 11, 2005 at http://www.amgen.com/
media/mediaipridetail .j sp?releaseID:673490&year:200 5.
Parkinson’s Disease Foundation, “Background Information on
GDNFiA Timeline,” Science News, as published on the internet

primate brain demonstrated using computerized tomography and

Sep.

magnetic resonance imaging,” J Neurosurg. 98:584-590 (2003).
Nutt et al., “Randomized, double-blind trial of glial cell line-derived

&selectedItem:238.

8,

2005

at

neurotrophic factor (GDNF) in PD,” Neurology 60:69-73 (2003).

* cited by examiner

http://www.pdf.org/news/news.cfm?type:l

US. Patent

Figure 1(a)

Feb. 3, 2015

Sheet 1 015

US 8,946,151 B2

US. Patent

Feb. 3, 2015

Figure 1(b)

P= Putamen
L=Lateral Ventricle

Sheet 2 015

US 8,946,151 B2

US. Patent

Feb. 3, 2015

Sheet 3 0f 5

US 8,946,151 B2

Figure 2(a)-(b)

Patient Reported Outcomes (PDQ-39) Ina :"
+Base|ine
so -

+Month 12

+Month 24
50
40

2

3
m

30 -

C!
o
n.
20 <

10 ~

0

I

MOB

ADL

PAI

COM

cos

I

soc

sm

EWB

PDQ Scale

F

SF-36 Score

Patlent Reported outCOITBS

90 -

80 .

+ Normal (45-64)
+ Baseline
“.- Month 12
+ Month 24

PF

RP

BP

SF

RE

US. Patent

2@0:705;3: owmwm@N~ca5zhrog3ms0e;2
2953m

Feb. 3, 2015

=0wNS2£21
g3&3
83Hoil
0%

Sheet 4 0f 5

8=0023$.02=51=53MS~.=H2 30

NH=53£53EH00$58-0=0£6332$2-0mmHail:095 800$55a8inQ03QM=53E2EHQ$.50mm>=- < 05%mi;=03NH=53$.30200%5H.8-0 29500502E3mm0&33H8=53H$.03- $95$0=0OHM:3=53I$.80EH$3-0- =2395=030E3

m200@98(wto0M56a7s8n.2trEo0h3mD68n“

mioc?wn 2805

US 8,946,151 B2

=0@3M:@080=53I6H$2-05 6 0=0§5EN=8A53Q0:3$H=2=532050- =0232=£H=53E5g3=>2.=56
=
=0
G
mm
0.:
$
=53
=2
3
w:
=
H
£63
0
=
3
a
=
w
0
:56=00is,=28£033=53H3:$.80=- £ P562,5002:3$.21£63H2AxmlNH=5- :5600352%=53ENQM;£030%2“.5H- F2000m50.:33wQEEi£03EH.2-

US 8,946,151 B2
1

2

METHOD OF TREATING PARKINSON’S
DISEASE IN HUMANS BY
CONVECTION-ENHANCED INFUSION OF
GLIAL CELL-LINE DERIVED
NEUROTROPHIC FACTOR TO THE
PUTAMEN

with Parkinson’s Disease. Ann Neurol., 46(3):419-424
(1999); Kordower, J. H., et al., Neurodegeneration Prevented
by Lentiviral Vector Delivery of GDNF in Primate Models of
Parkinson’s Disease. Science, 290:767-773 (2000); Pal?, S.,
et al., Lentivirally Delivered Glial Cell Line-derived Neu
rotrophic Factor Increases the Number of Striatal Dopamin
ergic Neurons in Primate Models of Nigrostriatal Degenera
tion. J. Neurosci., 22:4942-4954 (2002); Tomac, A., et al.,
Protection and Repair of the Ni gro striatal Dopaminergic Sys
tem by GDNF In Vivo, Nature, 373:335-339 (1995)). How
ever, initial clinical trials involving ventricular delivery of
GDNF showed no statistically signi?cant differentiation of
the placebo and active treatment groups (Nutt, J. G., et al.,
ICV GDNF Study Group. Implanted intracerebroventricular.
Glial Cell Line-derived Neurotrophic Factor. Randomized,
Double-Blind Trial of Glial Cell Line-Derived Neurotrophic

This application is a continuation-in-part of US. applica
tion Ser. No. 10/784,547 ?led Feb. 23, 2004, which claims the
bene?t of US. Provisional Application No. 60/449,789 ?led
Feb. 24, 2003, which are hereby incorporated by reference in

their entirety.
FIELD OF THE INVENTION

The present invention relates generally to the ?eld of neu

robiology. More particularly, it concerns methods for treating

Factor (GDNF) in PD, Neurology, 60: 69-73 (2003)), perhaps

Parkinson’ s disease in humans and related methods of restor

because insu?icient amounts of GDNF reached critical target

ing atrophic dopaminergic neurons and protecting dopamin
ergic neurons at risk of degeneration are also described.

sites from the CSF (Ai, Y., et al., Intraputamenal Infusion in
20

Aging Rhesus Monkeys: Distribution and Dopaminergic

BACKGROUND OF THE INVENTION

Effects. J. Comp Neurol. 461: 250-26125 (2003); Kordower,
J. H., et al., (2000)).

Current treatments for Parkinson’s disease (PD) become
increasingly less ef?cacious as the disease progresses, and do

Consequently, there continues to exist a long-felt need for
effective methods for the treatment and prevention of PD in
humans. Accordingly, it is an object of the present invention

25

little to slow the underlying pathophysiological changes in

to provide methods of treating PD in humans comprising
intraputaminal convection-enhanced infusion of GDNF. This
and other such objectives will be readily apparent to the

the nigrostriatal dopaminergic system (Rascol, O., et al.,
Limitations of Current Parkinson’s Disease Therapy, Ann.

Neurol., 53 Suppl 3:S3-12 (2003); Romell, 1., et al., Rationale
for Current Therapies in Parkinson’s Disease, Expert Opin.

skilled artisan from this disclosure.
30

Pharmacother., 4:1747-1761 (2003)). Neurotrophic factors,
proteins which activate cell signaling pathways regulating
neuronal survival, differentiation, growth and regeneration,

SUMMARY OF THE INVENTION
A ?rst aspect of the present invention concerns a method of

offer promising therapy for treating dopamine neurons in PD,
but are dif?cult to administer clinically as they do not pass

treating Parkinson’s disease in a human comprising admin
35

through the blood brain barrier (Beck, K. D., et al., Mesen
cephalic Dopaminergic Neurons Protected by GDNF from

ceutically effective dose of a glial cell line-derived neu
rotrophic factor (GDNF) protein product to one or both
putamen of a human PD patient in need thereof. The GDNF

Axotomy-Induced Degeneration in the Adult Brain, Nature,
373:339-3416 (1995); Bjorklund, A., et al., Towards a Neu
roprotective Gene Therapy for Parkinson’s Disease: Use Of

40

Adenovirus, AAV and Lentivirus Vectors for Gene Transfer of
GDNF to the Nigrostriatal System in the Rat Parkinson

Model, Brain Res., 886:82-98 (2000)). Glial cell line-derived
neurotrophic factor (GDNF) is a trophic factor shown to
dramatically protect and enhance the function of dopamine
neurons in vitro and in vivo in rodents and monkeys (Beck, K.

ing an the amino acid sequence shown below in Table 1) or

the surprising discovery that convection-enhanced infusion
of r-metHuGDNF to one or both putamen of a PD patient by
45 means of at least one implantable pump and one or more

indwelling catheters results in dramatic anti-parkinsonian
and anti-dyskinetic effects which are further associated with

impressive re-innervation and/or restoration of dopamine
50

Recovery in Advanced Parkinsonian Monkeys. Brain, 125:
2191-2201 (2002); Grondin, R., et al., GDNF Increases
Stimulus-evoked Dopamine Release and Motor Speed in

disease. Furthermore, the methods described herein are use

ful in repairing neural pathways damaged by Parkinson’s
55

Clinicopathological Findings Following Intraventricular
Glial-Derived Neurotrophic Factor Treatment in a Patient

disease in humans. Speci?cally, the methods described herein
are capable of stimulating nerve regeneration, including re

innervation of damaged human brain tissue by dopaminergic
neurons. In a related aspectthere is provided a method of
increasing the function of dopaminergic neurons that com
60

prises convection-enhanced infusion of a pharmaceutically
effective dose of r-metHuGDNF to one or both putamen of a

human patient in need thereof using at least one implantable
pump and at least one catheter.
The present invention also concerns the use of a pharma

Regrowth After Damage by 1-Methyl-4-Phenylpyridinium.
J. Neurochem., 66:74-82 (1996); Kordower, J. H., et al.,

stores in previously dopamine de?cient neurons in human
patients af?icted with PD.
The methods of the present invention are contemplated to
restore neural cell function in a patient having Parkinson’s

Aged Rhesus Monkeys, J. Neurosci., 23:1974-1980 (2003);
Hebert M. A., et al., Functional Effects of GDNF in Normal
Rat Striatum: Presynaptic Studies Using In Vivo Electro
chemistry and Microdialysis. J. Pharm. Exp. Ther., 279:1 181 1190 (1996); Hebert M. A. and Gerhardt, G. A., Behavioral
and Neurochemical Effects of Intranigral GDNF Admini stra
tion on Aged Fischer 344 Rats. J. Pharm. Exp. Ther., 282:
760-768 (1997); Hou, J. G. G., et al., Glial Cell line-Derived
Neurotrophic Factor Exerts Neurotrophic Effects on Dopam
inergic Neurons In Vitro and Promotes Their Survival And

protein product includes, without limitation, a pharmaceuti
cally effective dose of r-metHuGDNF (a dimeric protein hav
variants and/or derivatives thereof. The invention is based on

D., et al., (1995); Bjorklund,A., et al., (2000); Gash, D. M., et
al., Functional Recovery in Parkinsonian Monkeys Treated
with GDNF, Nature, 380:252-255 (1996); Grondin, R., et al.,
Striatal GDNF Infusion Promotes Structural and Functional

istering a pharmaceutical composition comprising a pharma

65

ceutically effective amount of GDNF and at least one phar

maceutically acceptable vehicle, excipient, or diluent in the
preparation of a pharmaceutical composition for increasing
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the function of dopaminergic neurons, wherein the composi

uGDNF to the putamen, either unilaterally or bilaterally,

tion is administered to one or both putamen of a human in

using one or more single-port catheters.

need thereof via convection-enhanced infusion using at least

FIGS. 3(a) and 3(b) depicts the UPDRS scores for patients
at 0, 3, 6, 12, 18, and 24 months of convection-enhanced
infusion of r-metHuGDNF to the putamen, either unilaterally

one implantable pump and at least one catheter.

Additionally provided are methods of treating cognitive
disorders in humans that comprise administration of a phar

or bilaterally using one or more single-port catheters.

maceutically effective dose of r-metHuGDNF to one or both

DETAILED DESCRIPTION OF CERTAIN
PREFERRED EMBODIMENTS

putamen of a human patient in need thereof via convection
enhanced infusion using at least one implantable pump and at
least one catheter.

This invention is based on the discovery that convection

Another aspect of the present invention includes methods
of treating PD or cognitive disorders comprising the admin

enhanced infusion of GDNF to one or both putamen of a

human PD patient using at least one implantable pump and at
least one indwelling catheter results in surprisingly dramatic
anti-parkinsonian and anti-dyskinetic effects which are asso
ciated with impressive re-innervation and restoration of
dopamine stores in previously dopamine de?cient neurons.
Macromolecules like GDNF diffuse slowly in brain paren

istration of a pharmaceutically effective dose of r-metH
uGDNF to one or both putamen of a human in need thereof

via convection-enhanced infusion using at least one implant
able pump and at least one catheter and assessing dopamin

ergic function in the brain of said human pre-operatively, and,
optionally, assessing dopaminergic function in the brain of
said human periodically post-operatively.

20

The methods disclosed herein may also provide a prophy
lactic function in humans. More speci?cally, one embodi
ment of the present invention includes a method of preventing
PD in a human comprising administration of r-metHuGDNF

chyma and usually over only short distances (Bobo, R. H., et
al., Convection-Enhanced Delivery of Macromolecules in the
Brain. Proc. Nat. Acad. Sci USA, 91:2076-2080 (1994)).
Convection enhanced delivery (CED) to the brain uses bulk
?ow in the extracellular space that results from a pressure

to one or both putamen of a human via convection-enhanced 25

gradient to signi?cantly enhance tissue penetration and dis

infusion using at least one implantable pump and at least one

tribute macromolecules over larger volumes in relatively

catheter. Another embodiment of the present invention

homogenous concentrations and largely independent of

includes methods of preserving dopaminergic neural cell

molecular weight. This is in stark contrast to diffusion that is
dependent on establishing a concentration gradient and

function in a human having, or at risk of having, a neurode

generative disorder comprising administration of r-metH

30

uGDNF to one or both putamen of a human via convection

enhanced infusion using at least one implantable pump and at
least one catheter. The neurodegenerative disorder may be

Parkinson’s disease or multiple system atrophy (MSA).
According to the invention, r-metHuGDNF administered via

35

convection-enhanced infusion to the human putamen is con

Enhanced Delivery to the Striatum: a Systematic Examina
tion of Rate of Infusion, Cannula Size, Infusate Concentra

tion, and Tissue-Cannula Sealing Time, J. Neurosurg.,
90:315-20 (1999); Hamilton, J. F., et al., Heparin Coinfusion
During Convection-Enhanced Delivery (CED) Increases the

templated to preserve the integrity of the nigrostriatal path
way in the human brain. Prophylactically administering
GDNF via convection-enhanced infusion of r-metHuGDNF
in accordance with the invention is contemplated as a method

depends heavily on molecular weight (Bobo, et al., (1994);
US. Pat. Nos. 5,720,720, 6,093,802 and 6,184,200 (the US.
patents are hereby incorporated by reference in their
entirety); Chen, M. Y., et al., Variables Affecting Convection

40

Distribution of the Glial-Derived Neurotrophic Factor

(GDNF) Ligand Family in Rat Striatum and Enhances the

of preventing or treating degeneration of the nigrostriatal
pathway or loss of functional dopaminergic activity associ

Pharmacological Activity of Neurturin, Exp. Neurol., 168:

ated with a neurodegenerative disorder. The neurodegenera
tive disorder prevented or treated includes Parkinson’s dis

155-61 (2001); Nguyen, T. T., et al., Convective Distribution
of Macromolecules in the Primate Brain Demonstrated Using

ease and MSA.

45

Computerized Tomography and Magnetic Resonance Imag
ing, J. Neurosurg., 98:584-90 (2003)). In a recent study in

nonhuman primates (Gash, et al., unpublished data), GDNF

BRIEF DESCRIPTION OF THE DRAWINGS

was seen to have an average area of distribution of 3 1 :8 mm2

FIGS. 1(a) and 1(b) illustrate the placement of multiport
infusion catheters (represented by white circles except patient
6, represented by a black circle for clarity). Images were
normalized to the Talirach atlas in Analyze version 5.0, and
the catheter locations mapped to a single axial slice level (+4
mm). The target for multiport catheter placement was the
mid-dorsal putamen. Numbers indexing each location repre

50
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when delivered with a single port catheter (1 mm in diameter
with a 0.25 mm diameter port at the tip; Medtronic model
8770IP1A) and 119116 mm2 with a multiport catheter (1 mm
in diameter with 24 ports, each 0.075 mm in diameter;

Medtronic model 877OIP24A) using the same pump delivery
parameters. This ?nding is consistent with other studies that
show convection-enhanced infusion distributes large mol

sent the corresponding patient designation. The reference

ecules far more extensively at a relatively homogenous con

anatomic underlay is the Talairach-normalized average

centration as compared to diffusion alone (Lieberman, D. M.,
et al., Convection-Enhanced Distribution of Large Molecules

T1-weighted image with superimposed lenticular nucleus
map (dark greyiputamen; light grenglobus pallidus) from
the ten subjects. LiPatient Left. Scale Bar (top right)410

60

mm.

FIGS. 2(a) and 2(b) depicts patient assessments made
using validated quality of life questionnaires: the 39-item
Parkinson’s Disease Questionnaire (PDQ 39; FIG. 2(a)) and
the 36-item Medical Outcomes Study short form health sur

65

in Gray Matter During Interstitial Drug Infusion, J. Neuro
surg., 82:1021-1029 (1995)).
One aspect of the present invention provides methods of
treating or preventing neurodegenerative disorders in a
human that comprise administering a pharmaceutical com
position comprising a pharmaceutically effective amount of a
GDNF protein product and at least one pharmaceutically

vey (SF-36; FIG. 2(b)) before surgery and after 3, 6, 12, 18,

acceptable vehicle, excipient, or diluent to one or both puta

and 24 months of convection-enhanced infusion of r-metH

men of a human in need thereof via convection-enhanced

US 8,946,151 B2
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infusion using at least one implantable pump and at least one
catheter. The neurodegenerative disorder may be Parkinson’ s

surprising and unexpected in that they are not consistent with
the known dopaminergic circuitry of the basal ganglia, but are
consistent with crossed glutamatergic projections from the
motor cortex (Barbeito, L., et al., Activation of the Bilateral

disease or MSA.

In another embodiment of the present invention, in con
junction with the above and below embodiments, at least one

Corticostriatal Glutamatergic Projection by Infusion of

catheter is a multiport catheter. Additionally (or alterna
tively), the infusion may be pulsed.

GABA into Thalamic Motor Nuclei in the Cat: an In Vivo

Release Study, Neuroscience, 28:365-374 (1989); Glowin

In another embodiment of the present invention, in con
junction with the above and below embodiments, at least one
catheter may be a single-port catheter from about 1 mm in
diameter to about 0.5 mm in diameter and wherein the port is

ski, 1., et al., Role of the Thalamus in the Bilateral Regulation
of Dopaminergic and GABAergic Neurons in the Basal Gan

glia. Ciba Found Symp. 107:150-163 (1984)).

prises administering a pharmaceutical composition compris

Accordingly, effective methods of treating or preventing
the pathological hallmarks of Parkinson’s disease in humans
as well as the devastating symptoms of PD are provided by the
present invention.
The section headings used herein are for organizational

ing a pharmaceutically effective amount of a GDNF protein

purposes only and are not to be construed as limiting the

at its distal end. Additionally (or alternatively), the infusion
may be pulsed.
Another embodiment of the present invention provides a
method of treating Parkinson’ s disease in a human that com

subject matter described.

product and at least one pharmaceutically acceptable vehicle,

Abbreviations

excipient, or diluent to one or both putamen of a human in

need thereof via convection-enhanced infusion of the phar
maceutical composition using at least one implantable pump

20

In the preceding description and the experimental disclo
sure which follows, the following abbreviations apply:

and at least one catheter with a single port at its distal end.

Another embodiment of the present invention provides a
method of treating Parkinson’ s disease in a human that com

prises administering a pharmaceutical composition compris

25

6—OHDA

6—hydroxydopamine

ALS
ASA

amyotrophic lateral sclerosis
acute systemic anaphylaxis

ing a pharmaceutically effective amount of a GDNF protein

AUC

area under the concentration vs time curve

product and at least one pharmaceutically acceptable vehicle,

CAPIT

Core Assessment Program for Intracerebral

excipient, or diluent to one or both putamen of a human in

CAPS

3—(cyclohexylamino)—l—propanesulfonic acid

CHO
CI

Chinese hamster ovary
continuous leLlSlOH

CSF

cerebrospinal fluid

CT
DA

computed tomography
dopamine, dopaminergic

need thereof via convection-enhanced infusion of the phar
maceutical composition using at least one implantable pump

Transplantations
30

and at least one catheter with a single port at its distal end and

wherein the infusion of the composition is pulsed.
The methods of the present invention may comprise con

DOPAC

3,4—dihydroxyphenylacetic acid

tinuous and/ or pulsed delivery of GDNF through one or more

E. coli

Escherichia coli

catheters with a diameter of about 1 mm to about 0.5 mm and 35

FCA
GDNF
GLP

Freund’s Complete Adjuvant
glial cell line—derived neurotrophic factor
Good Laboratory Practice

HPLC

high—performance liquid chromatography

HVA
ICV
IM

homovanillic acid
intracerebroventricular
intramuscular

ISN

intranigral

IT
IV

intrathecal
intravenous

having a single port at its distal end to promote convection
enhanced distribution of GDNF which allows local tissue
concentrations of GDNF to reach threshold levels. In some

embodiments of the invention, the method comprises con
tinuous and/ or pulsed delivery of GDNF utiliZing one or more

40

catheters with a diameter of about 0.8 mm to about 0.6 mm

and having a single port at its distal end to promote convection
enhanced distribution of GDNF which allows local tissue
concentrations of GDNF to reach threshold levels. In other
embodiments of the invention, the method comprises con
tinuous and/ or pulsed delivery of GDNF utiliZing one or more
catheters with a diameter of about 0.6 mm and having a single
port at its distal end to promote convection enhanced distri
bution of GDNF which allows local tissue concentrations of
GDNF to reach threshold levels.

45
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3,4-dihydroxyphenylalanine (levodopa)
recombinant—methionyl human GDNF

PD

Parkinson’s disease

PET

positron—emission tomography

pmn
Ret
r—metHuGDNF

progressive motor neuropathy
receptor tyrosine kinase
recombinant—methionyl human GDNF

SC

subcutaneous

SDS—PAGE

sodium dodecylsulfate-polyacrylamide gel

electrophoresis

Unilateral delivery of GDNF by a pulsed ?ow sequence
administered contralaterally to the most affected side using a

multi-port catheter resulted in motor improvement bilaterally
comparable to improvement seen for bilateral putamenal
GDNF continuous using a 0.6 mm diameter single port cath

L—dopa
r—metHuGDNF

55

SEM

standard error of the mean

TGF
TH

transforming growth factor
tyrosine hydroxylase

TH+

tyrosine hydroxylase positive

UPDRS

Uni?ed Parkinson’s Disease Rating Scale

eter (Gill, et al., (2003)). With both approaches, the total
UPDRS scores improved in OFF and ON after 6 months of
GDNF treatment. Timed motor tests also improved, with
improvements seen in both ON and OFF. Patients adminis
tered GDNF contralaterally to the most affected side, did not

DEFINITIONS

experience aphthous mouth ulcers and only two reported mild

Unless otherwise noted, technical terms are used according
to conventional usage. As utilized in accordance with the

Lhermitte’s syndrome. Bilateral effects were observed in all

present disclosure, the following terms shall be understood to

ten subjects. These bilateral improvements associated with

have the following meanings:

60

unilateral GDNF treatment as disclosed herein support a

facilitatory effect of improved function in the ipsilateral puta
men on bilateral motor pathways. Furthermore, the apparent
bilateral effects from unilateral administration of GDNF are

65

As used herein, the term “catheter” refers to any tubular
medical device for insertion into a cavity, tissue, organ, or any
sub structure thereof of a living mammal to permit injection of
a therapeutic agent. As particularly used here, a catheter is

US 8,946,151 B2
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used to deliver r-metHuGDNF to the brain or substructures

ing, 8) quantal size of terminal dopamine release, 9) rate of
dopamine turnover, 10) TH+ cell count, 11) TH+ innervation
density and 12) TH+ ?ber density.

thereof such as the putamen. An “indwelling” catheter is one

that is implanted and left in place for protracted periods, such

The phrase “target site”, or a grammatical version thereof,

as ?fteen minutes or longer.

As used herein, the phrase “catheter system” refers to the

refers to the site for intended delivery of a substance, such as

combination of at least one catheter and at least one accessory

a drug. In particular embodiments of the present invention, a
preferred target site is an area of dopaminergic degeneration
or dopaminergic dysfunction within the brain of a human
af?icted with Parkinson’ s disease. More preferably, the target

device including, but not limited to, an anchor, stylet, guide
tube, guide wire or a combination thereof.
“Continuous delivery” or “chronic infusion” are inter
changeable and are intended to mean delivery of a substance
over a period of time such that the procedure is distinguished

site includes one or more site in the substantia nigra, globus

pallidus, caudate nucleus, and putamen. Even more prefer
ably, the target site includes the central area of the putamen.
Even more preferably, the target site includes the posterior

from “bolus” delivery. Continuous delivery generally
involves the delivery of a substance over a period of time
without interruption. The rate of delivery need not be con

area of the putamen. Most preferably, the target site includes
the postero-dorsal area of the putamen. Furthermore, a par

stant, and may be pulsed, and the period of delivery need not
be very long, i.e., the period of constant delivery may be over

ticular target site may be targeted unilaterally or bilaterally
with respect to the hemispheres of the brain.

a period of maybe half an hour or an hour or a few hours, but

may also be over a period of days, weeks, months, or even

“Proximal end” is a relative term, and generally refers to

years. A pulse consists of periodic increases in the ?ow rate
for intervals ranging from seconds to minutes, to hours,
which, as used herein, enhances convection enhanced deliv
ery of the drug into brain tissue.

the end of a device, such as a catheter that is nearest to the
20

“Admixing” as used herein denotes the addition of an

excipient to a polypeptide of interest, such as by mixing of dry
reagents or mixing of a dry reagent with a reagent in solution
or suspension, or mixing of aqueous formulations of reagents.
“Excipient” as used herein denotes a non-therapeutic agent
added to a pharmaceutical composition to provide a desired

consistency or stabilizing effect.
“Implanted” means placed within the body, and main

operator (i.e., the surgeon) and is furthest away from the
treatment site. In the present invention a catheter has a proxi
mal end that may be communicably attached to an access port
or drug delivery apparatus, such as a pump, or reservoir.

25

“Tyrosine hydroxylase-positive” or “TH+” is intended to
refer to the presence of tyrosine hydroxylase in a referenced
nervous tissue as indicated by the results from any technique
known in the art as a means to detect and/or measure tyrosine

hydroxylase, tyrosine hydroxylase encoding mRNA, or

tyrosine hydroxylase activity.
30

tained at that location for some extended period of time. As

used herein it is intended that the period of time during which
the implanted object is maintained in place will be, in general,
considerably greater than that customarily required to intro

“Distal end” is a relative term and generally refers to the
end of a device, such as a catheter, that is furthest away from

the operator (i.e., the surgeon) and is closest to the treatment
site. In the present invention the distal end of a catheter may
be communicably attached to an opening that allows for the

catheter used in a method of the invention may be placed

delivery of drug to the target site.
“Drug delivery apparatus” as used herein includes but is

within a tissue or organ such that the catheter so implanted is
intended to remain at the site of implantation for some

not limited to, a drug reservoir and/or a drug pump of any
kind, for example an osmotic pump, an electromechanical

duce a bolus of a substance, such as a drug. For example, a

35

extended period of time. Some of the drug delivery appara
tuses that may be used in the methods of the invention, for

pump, an electroosmotic pump, an effervescent pump, a
40

example the drug pumps and/or catheters, are designed to be
implanted for periods greater than a month and even years and

to deliver drug during this period. A drug delivery apparatus
may be implanted, for example, subcutaneously, or within a
tissue or organ, or within a body cavity such as the peritoneal

45

hydraulic pump, a piezoelectric pump, an elastomeric pump,
a vapor pressure pump, or an electrolytic pump. Preferably,

such a pump is implanted within the body.
Throughout this speci?cation, reference to the term
“GDNF” or the phrase “GDNF protein product” or “GDNF
polypeptide”, all of which are used interchangeably, refers to

cavity, infraclavicular space, the thoracic cavity, the pelvic

glial cell line-derived neurotrophic factor from any species,

cavity, or any other cavity or location that is convenient for
delivery of the intended substance. A catheter may be

preferably human, in native sequence or in genetically engi

implanted into a tissue, for example into brain tissue, and may
be af?xed in place by ?xing the catheter to another tissue,

including murine, bovine, ovine, porcine, equine, avian, and
50

such as bone, e.g., the skull, or cartilage, using an adhesive or
screws, clamps, sutures or any other suitable ?xing means.

The phrases “dopaminergic dysfunction”, “dopaminergic
dysregulation”, “dopaminergic degeneration”, “dopamine
depleted”, “dopamine de?cient”, or grammatical equivalents

thereof, and from any source, whether natural, synthetic, or

recombinantly produced.
55

thereof, may be used interchangeably herein. All such phrases
are intended to encompass at least one of the following con

ditions or disorders: Parkinson’s disease, neuronal dopamine
de?cit, dopaminergic neuron de?cit, dopaminergic neuron

lesions, hypo-dopaminergic innervation, dopamine synthesis
incapacity, dopamine storage incapacity, dopamine transport

60

incapacity, or dopamine uptake incapacity. Dopaminergic
but not limited to, the following: 1) the number of TH express

ing neurons 2) size of dopamine neuronal cells 3) dopamine

Exemplary GDNF polypeptides useful in the present
invention include, without limitation, any of GDNF protein
products described in Us. Pat. Nos. 5,731,284, 6,362,319,
6,093,802, and 6,184,200 (all of which are hereby incorpo
rated by reference in their entireties). Preferred GDNF pro
tein products for use in the methods of the present invention
include, but are not limited to, r-metHuGDNF, a recombinant
GDNF protein produced in E. coli which has an amino acid
sequence identical to native mature human GDNF with the
addition of an amino terminal methionine. Thus, r-metH
uGDNF consists of 135 amino acids. Seven of the amino

dysfunction can be evidenced by analyzing factors including,

metabolite levels 4) dopamine uptake, 5) dopamine transport,
6) neuronal dopamine uptake, 7) dopamine transporter bind

neered variant form, including, without limitation, biologi
cally active fragments, analogs, variants, (including, inser
tion, substitution, and deletion variants) and derivatives

65

acids are cysteines, which are involved in one intermolecular

disul?de bond and three intramolecular disul?de bonds. In its
active form, r-metHuGDNF is a disul?de-bonded

US 8,946,151 B2
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homodimer. The primary amino acid sequence of monomeric
r-metHuGDNF (SEQ ID NO: 1) is provided in Table 1.

other pharmaceutically-acceptable excipients for modifying
or maintaining the pH, osmolarity, viscosity, clarity, color,

TABLE 1

sterility, stability, rate of dissolution, or odor of the formula
tion. A preferred pharmaceutical composition of GDNF com
prises a therapeutically effective amount of at least one

Primar

Amino Acid Sequence of r—metHuGDNF

GDNF protein and a pharmaceutically acceptable vehicle.
More preferably, the pharmaceutically acceptable vehicle is
an aqueous buffer. More preferably, the vehicle comprises

Amino
Acid

Primary Amino Acid Sequence
HZN—

sodium chloride at a concentration of about 100 mM to about
200 mM and sodium citrate at a concentration of about 5 mM

No.

Ser Pro Asp Lys Gln Met Ala Val Leu Pro

10

Arg Arg Glu Arg Asn Arg Gln Ala Ala Ala

20

Ala Asn Pro Glu Asn Ser Arg Gly Lys Gly

30

Arg Arg Gly Gln Arg Gly Lys Asn Arg Gly

40

Cys Val Leu Thr Ala Ile His Leu Asn Val

50

Thr Asp Leu Gly Leu Gly Tyr Glu Thr Lys

60

Glu Glu Leu Ile Phe Arg Tyr Cys Ser Gly

70

Ser Cys Asp Ala Ala Glu Thr Thr Tyr Asp

8O

Lys Ile Leu Lys Asn Leu Ser Arg Asn Arg

90

Arg Leu Val Ser Asp Lys Val Gly Gln Ala

lOO

Cys Cys Arg Pro Ile Ala Phe Asp Asp Asp

110

Leu Ser Phe Leu Asp Asp Asn Leu Val Tyr

120

His Ile Leu Arg Lys His Ser Ala Lys Arg

130

Cys Gly Cys Ile COOH

134

to about 20 mM. Even more preferably, the vehicle comprises

Met

sodium chloride at a concentration of about 125 mM to about
175 mM and sodium citrate at a concentration of about 7.5
mM to about 15 mM. Even more preferably, the vehicle
comprises sodium chloride and sodium citrate at a concen

tration of about 150 mM and about 10 mM, respectively. Most

preferably, the GDNF pharmaceutical composition is formu
lated as a liquid with 10 mM sodium citrate and 150 mM
sodium chloride at a pH of5.0.
20

25

The GDNF protein products useful in the present invention
may be isolated or generated by any means known to those

30

erence).
Once the therapeutic composition has been formulated, it
may be stored in sterile vials as a solution, suspension, gel,
emulsion, solid, or dehydrated or lyophilized powder. Such
formulations may be stored either in a ready to use form, a

35

lyophilized form requiring reconstitution prior to use, or a

liquid form requiring dilution prior to use. Preferably, the
GDNF pharmaceutical composition is provided in sterile
single-use vials at a concentration of 10 mg/mL and stored at
a temperature of —2-80 C. until use. Immediately prior to
40

useful in the present invention are described in US. Pat. Nos.

administration, the GDNF protein product should be thawed
and appropriately diluted with a sterile citrate buffered saline

6,362,319, 6,093,802 and 6,184,200 (all ofwhich are hereby
incorporated by reference in their entireties).
GDNF pharmaceutical compositions typically comprise a
therapeutically effective amount of at least one GDNF protein
product and one or more pharmaceutically and physiologi

product. Such formulation agents are those substances known
to artisans skilled in formulating sustained release formula
tions. For further reference pertaining to pharmaceutically

and physiologically acceptable formulation agents, see, for
example, Remington’s Pharmaceutical Sciences, 18th Ed.
(1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435
1712 (the disclosure of which is hereby incorporated by ref

skilled in the art. Preferably, GDNF is recombinantly pro
duced. In a preferred method, the GDNF is cloned and its
DNA expressed, e.g., in mammalian cells or bacterial cells.

Exemplary methods for producing GDNF protein products

The GDNF pharmaceutical composition may contain still
other pharmaceutically-acceptable formulation agents for
modifying or maintaining the rate of release of GDNF protein

(pH 5.0) consisting of 150 mM sodium chloride and 10 mM

45

sodium citrate.
In the methods of the present invention, GDNF is chroni
cally administered to a site of dopaminergic dysfunction in
the human brain by means of an implantable pump and one or

cally acceptable formulation agents. Suitable formulation

more catheters. The region of a PD patient’ s brain targeted for

agents include, but are not limited to, antioxidants, preserva

chronic delivery of GDNF may be determined by assessing

tives, coloring, ?avoring and diluting agents, emulsifying
agents, suspending agents, solvents, ?llers, bulking agents,
buffers, vehicles, diluents, excipients and/or pharmaceutical

biomarkers of PD disease or disease progression including,
but not limited to, the number of TH expressing neurons 2)

adjuvants. For example, a suitable vehicle may be, physi
ological saline solution, citrate buffered saline, or arti?cial
CSF, possibly supplemented with other materials common in
compositions for parenteral administration. Neutral buffered

50

size of dopamine neuronal cells 3) dopamine metabolite lev

els 4) dopamine storage, 5) dopamine transport, 6) neuronal
dopamine uptake, 7) dopamine transporter binding, 8) quan
55

saline or saline mixed with serum albumin are further exem

plary vehicles. Those skilled in the art would readily recog
nize a variety of buffers that could be used in the composi
tions, and dosage forms used in the invention. Typical buffers
include, but are not limited to pharmaceutically acceptable
weak acids, weak bases, or mixtures thereof. Preferably, the

infused directly into a region of the human brain which is

60

severely dopamine depleted. The region of a PD patients
brain which is severely dopamine depleted and, therefore, a
target for chronic delivery of GDNF may be determined by
neuroimagery of the brain, or regions thereof. The neuroim
agery technique used to determine the site of chronic infusion
of GDNF may be selected from the group consisting of 18F

buffer components are water soluble materials such as phos

phoric acid, tartaric acids, lactic acid, succinic acid, citric

?uorodopa positron emission tomography (lsF-dopa PET)13,

acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid,
and salts thereof.
The primary solvent in a vehicle may be either aqueous or
non-aqueous in nature. In addition, the vehicle may contain

tal size of terminal dopamine release, 9) rate of dopamine
turnover, 10) TH+ cell count, 11) TH+ innervation density
and 12) TH+ ?ber density. For instance, GDNF may be

65

123 l-2[3 -carboxymethoxy-3 [3-(4-iodophenyl)tropane uptake
on single-photon emission tomography (1231-[3-CIT SPECT),
and similar techniques. In a preferred embodiment of the

US 8,946,151 B2
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present invention, GDNF is infused directly into at least one

these Patent Applications and United States patents is hereby

dopaminergic dysfunctional putamen of a PD patient. Even
more preferably, GDNF is infused directly into the posterior
region of at least one dopaminergic dysfunctional putamen of
a PD patient. Mo st preferably, GDNF is infused directly into
at least one dopaminergic dysfunctional postero-dorsal puta

incorporated by reference into this speci?cation.
The methods of the present invention are also achievable

by infusion of GDNF utiliZing a multiport catheter. A multi
port catheter is a catheter having a plurality of infusion holes
or ports disposed along the length of the catheter or catheter
tip. Generally, a multiport catheter will have said infusion

men of a PD patient.

holes or ports longitudinally spaced along the tip length at
substantially regular intervals. A multiport catheter therefore

A number of drug delivery apparatus, catheters, catheter
systems and combinations thereof have been developed for
the dispensing of medical substances to speci?c sites within

may have about 20 to about 60 ports, about 30 to about 50
ports, or about 35 to about 45 ports, along its length or the

the body and are all readily available to those skilled in the art
for use in the methods of the present invention. Therefore, one

length of the catheter tip. A catheter useful in the methods of

may use prior art drug delivery devices, catheters, and cath
eter systems for delivering the GDNF compositions to the
target site of the brain of the patient at speci?ed concentra
tions and/or at speci?ed times and/or at different delivery
rates. By way of illustration and not limitation, in the methods
of the present invention one may use the technology
described in U.S. patent Publication No. US20030120262,
US20030208184, or US20030225372 orU.S. Pat. No. 4,931,

the present invention includes, but is not limited to, an intra

putamenal (IPA) multiport catheter having 40 ports arranged
4 per 0.5 mm placed approximately every 90°, about 5 mm

length, such as model #10532, manufactured by Medtronic,
Inc. (Minneapolis, Minn.), or any catheter substantially simi
20

050, 4,838,887, 5,207,666, 4,714,462, 5176,641; 3,923,060,
4,003,379, 4,588,394, 4,447,224, 5,575,770, 4,978,338,

infused directly into one or both putamen of a human PD

patient. The phrase “therapeutically effective dose” or “phar
maceutically effective dose”, which are used interchangeably

5,908,414, 5,643,207, 6,589,205 or 6,592,571. The entire
disclosure of each of these U.S. Patent Applications and U.S.

Patents is hereby incorporated by reference into this speci?

25

cation. A preferred drug delivery apparatus useful in the con
Pat. No. 5,752,930 or U.S. patent application No.

US20030216714 (which are hereby incorporated by refer

skilled in the relevant art. In a preferred embodiment of the
30

ratus useful in the context of the present invention includes

one described in U.S. Pat. No. 6,620,151 (which is hereby
incorporated by reference in its entirety). An even more pre
ferred drug delivery apparatus useful in the context of the
present invention includes one described in U.S. patent appli

herein, refers to that amount of GDNF suf?cient to result in

any amelioration, impediment, prevention or alteration of any
biological symptom generally associated with a neurodegen
erative disorder including, without limitation, PD by one

text of the present invention includes one described in U.S.

ence in their entireties). A more preferred drug delivery appa

lar thereto.
In another embodiment of the methods of the present
invention, in conjunction with any of the above or below
embodiments, a therapeutically effective dose of GDNF is

present invention, in conjunction with any of the above or
below embodiments, GDNF is directly into a human putamen
at a dose of about 1 ug/putamen/day to about 100 ug/putamen/
day. More preferably, GDNF is infused directly into a human
putamen at a dose of about 5 ug/putamen/day to about 50

35

ug/putamen/day. Even more preferably, GDNF is infused
directly into a human putamen at a dose of about 10 ug/puta

cation No. US20030216714 (which is hereby incorporated by
reference in its entirety). Most preferably the drug delivery

men/ day to about 75 ug/putamen/ day. Even more preferably,

apparatus used in the context of the present invention is one
described in U.S. Pat. No. 4,146,029, 4,013,074, or 4,692,

about 15 ug/putamen/day to about 50 ug/putamen/ day. Even

147, (which are hereby incorporated by reference in their
entireties) commercial embodiments thereof including, but
not limited to, the Synchromed® I, Synchromed® EL, and
Synchromed® II infusion pumps (Medtronic, Inc., Minne

GDNF is infused directly into a human putamen at a dose of
40

more preferably, r-metHuGDNF is infused directly into a
human putamen at a dose of about 20 ug/putamen/day to
about 45 ug/putamen/day. Even more preferably, r-metH
uGDNF is infused directly into a human putamen at a dose of

45

more preferably, r-metHuGDNF is infused directly into a
human putamen at a dose of about 30 ug/putamen/day to

apolis, Minn.).
In another embodiment of the present invention, in con
junction with any of the above or below embodiments, a
number of catheters and catheter systems have been devel

about 25 ug/putamen/day to about 40 ug/putamen/ day. Even
about 35 ug/putamen/ day. Mo st preferably, r-metHuGDNF is

oped for the dispensing of agents, such as drugs, to speci?c

infused directly into a human putamen at a dose of about 30

sites in the body and are readily available to those skilled in
the art for use in the methods of the present invention. By way
of illustration and not limitation, in the methods of the present

ug/putamen/day.
50

Applicants also disclose herein the use of a pharmaceuti
cally effective amount of GDNF including, but not limited to,
r-metHuGDNF, and at least one pharmaceutically acceptable
vehicle, excipient, or diluent in the preparation of a pharma
ceutical composition for treating cognitive disorders or inhib

55

iting cognitive decline associated with neurodegenerative
disorders, including, without limitation, PD and dementia,

invention one may use the technology described in U.S.

patent Publication No. 20030216700, 20030199831, or
20030199829 or U.S. Pat. No. 6,319,241. The entire disclo
sure of these U.S. Patent Applications and the United States

patent is hereby incorporated by reference into this speci?
cation.
The methods of the present invention are also achievable

by infusion of GDNF utiliZing a single port catheter. A single
port catheter is a catheter having one hole or port, generally
disposed at the distal end of the catheter. Accordingly, a
catheter or catheter system useful in the context of the present
invention includes, but is not limited to, an intraparenchymal
infusion catheter or catheter system described in International

60

Patent Application Publication No: WO 02/07810, WOO3/

65

002170, or WO 03/077785, or U.S. Pat. No. 5,720,720, 6,551,
290, 6,093,180 or 6,609,020. The entire disclosure ofeach of

wherein the composition is for administration to one or both
putamen of a human in need thereof via convection-enhanced
infusion using at least one implantable pump and at least one
catheter. In a preferred use of a pharmaceutically effective
amount of GDNF and at least one pharmaceutically accept
able vehicle, excipient, or diluent in the preparation of a

pharmaceutical composition for treating cognitive disorders
or inhibiting cognitive decline associated with neurodegen
erative disorders, including, without limitation, PD and
dementia, the composition is for administration to a site of
dopaminergic dysfunction within one or both putamen of a

US 8,946,151 B2
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human in need thereof via convection-enhanced infusion
using at least one implantable pump and at least one catheter.

agree to abstinence or use of barrier methods of birth control

For such uses dopaminergic dysfunction is pre-operatively. In
another embodiment of the present invention, in conjunction

prior exposure to neuroleptics or used selegiline for two
months prior to implantation of the catheter. For the two

with any of the above or below embodiments

months prior to the study patients had had stable symptoms

during the study unless surgically sterile. No patients had had

The inventive method has the effect, upon application to

and had been maintained on a constant regimen of anti-PD

parkinsonian patients, of signi?cantly reducing symptoms of

medications consisting of L-dopa and/ or a dopamine agonist

Parkinson’s disease, the resulting improved condition of the

(range 300-2500 mg/day levodopa equivalents, see Nutt, J.
G., et al., (2003)); a catechol-o-methyltransferase inhibitor
(COMT) had been used by two subjects and amantadine by
two patients. No changes were made inpatients’ anti-PD drug
regimens during the course of the study.

patient continuing for at least 30 months. In particular, a clear
improvement of disease-speci?c symptoms was obtained
with the inventive method insofar as motoricity, ?ne motor

icity, and ?ne dexterity. In addition, mobility and concentra
tion power was increased and reaction time was decreased.

Pronunciation, facial expressiveness, posture, sense of smell,

TABLE 2

libido, sexual function, and emotional condition were
improved and state of mind was brightened.
In yet another embodiment of the present invention, GDNF

Patient Data, Side-Effects, and Other Effects of GDNF
Patient #

can be used as a cognitive enhancer, to enhance learning,
particularly as a result of dementias or trauma, or to inhibit

cognitive decline and/or dementia, for example, in patients

20

with PD. Alzheimer’s disease, which has been identi?ed by

Age (years)

the National Institutes of Aging as accounting for more than
50% of dementia in the elderly, is also the fourth or ?fth
leading cause of death in Americans over 65 years of age.
Four million Americans, 40% of Americans over age 85 (the

Duration of disease (years)

fastest growing segment of the US. population), have Athe
imer’s disease. Twenty-?ve percent of all patients with Par

L—Dopa equivalents/day

4

5

70
5.6
450

54
5.2
300

49
11.4
1275

61
15.4
902

48
7.9
750

Lhermitte’s

+

Hyponatraemia
Improved Bladder Control
Recovery of Sexual Function
30 Improvement in Taste/ Smell
Reduction in Hypomimia*

+
+

+

+

(010*
Reduced Hypophonia

+

+

+

+

+

+

+

+

+

+

+

(Off and On)*
35

EXAMPLES

Improved Postural Stability

(010*
Decreased End—of—Dose

Fluctuations*
Decreased Dyskinesia*

The following examples, including the experiments con

+

+

DELIVERY SYSTEM
40 EFFECTS

Example 1
Unilateral Intraputamenal GDNF Improves Bilateral

3

Change in medications

or Atheimer’s disease-like dementia associated with PD.

ducted and results achieved are provided for illustrative pur
poses only and are not to be construed as limiting the inven
tion.

2

25 after 6 mo.
Taste Abnormalities

kinson’s disease also suffer from Atheimer’s disease-like
dementia. Applicants have shown here for the ?rst time that

chronic intraputaminal administration of GDNF has applica
tion in treating or preventing cognitive disorders in humans.
In particular, intraputaminal administration of GDNF has
application in treating or preventing cognitive disorders and/

1

Headaches

+

+

+

+

+

MRI Changes

+

+

+

+

+

Pump Related Discomfort

+

+

+

+

+

45

Patient #

Motor Functions in Patients with Parkinson’s
Disease

10

Age (years)

Methods

Subjects
Consent from the patients described in Example 1 was
obtained in accordance with the FDA and the local University
of Kentucky Medical Center Internal Review Board regula
tions and guidelines. Patients were diagnosed with idiopathic
PD according to standard criteria (Hughes, A. 1., et al., What
features improve the accuracy of clinical diagnosis in Parkin

50 Duration of disease (years)

L—Dopa equivalents/day

55

dependence/abuse, and inability or unwillingness to comply
with long-term follow-up. Premenopausal subjects had to

69
12.2
1200

68
11.8
2500

47
6.8
500

+

+

+

+

+

+

+

+

+

+

+

+

+

+

after 6 mo.
Taste Abnormalities

+

Lhermitte’s

+

Hyponatraemia
Improved Bladder Control
Recovery of Sexual Function
Improvement in Taste/ Smell

42:1 142-1 146 (1992)). Eight men and two women, aged 47 to
70 years (see Table 2), with moderate to severe idiopathic PD

ease duration ranging from 4.8 to 15 .4 years (Table 2). Exclu
sion criteria included the presence of clinically signi?cant
depression or dementia, concomitant disease likely to inter
fere with the study, prior surgery for PD, drug or alcohol

63
6.2
1775

Change in medications

son’s disease: A clinicopathologic study?, Neurology,
(Hoehn and Yahr Stage 3-4) were selected for the study.
Primary symptoms were rigidity and bradykinesia with dis

50
4.8
700

Reduction in Hypomimia*

60

(010*
Reduced Hypophonia (Off

and On)*
Improved Postural Stability

+

(010*
Decreased End—of—Dose

65 Fluctuations*
Decreased Dyskinesia*

+
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TABLE 2-continued

dose level for an extended period. All ten subjects requested
continuation of the GDNF infusions.

Clinical Testing and Follow Up

Patient Data, Side—Effects, and Other Effects of GDNF

Clinical evaluations were based on 1) UPDRS Total ON

DELIVERY SYSTEM
EFFECTS

and OFF Scores, 2) UPDRS Motor ON and OFF Scores and

Headaches

+

+

+

+

+

MRI Changes
Pump Related Discomfort

+
+

+
+

+
+

+
+

+
+

3) the Clinical Assessment Program for Surgical Interven
tional Therapies in Parkinson’s Disease CAPSIT-PD (Defer,
G-L., Core assessment program for surgical interventional
therapies in Parkinson’s disease (CAPSIT-PD). Mov Dis.,
14:572-584 (1999)). All patients were evaluated using total

Duration of disease is from onset of symptoms to week prior to surgery.

L-Dopa Equivalents based on Nutt, J. G., et al., (2003).
Reduction in hypomimia (question 19, section 3 UPDRS).
Reduced hypophonia (question 5, section 2 and question 18, section 3 UPDRS).

UPDRS and CAPSIT-PD timed motor tests, and were

requested to keep a personal diary. Required visits were
scheduled weekly during the ?rst fourweeks of the study after
pump implant. Thereafter, visits were scheduled monthly
through the 24 weeks of GDNF therapy with a ?nal follow-up

Improved postural stability (questions 29 & 30, section 3 UPDRS).
Decreased end ofdose ?uctuations (questions 36-39, section 4 UPDRS).

Decreased dyskinesia (questions 32-34, section 4 UPDRS).

visit to assess the effects of GDNF washout.

Surgical Procedures
Each patient had an MRI-based stereotactic implantation
of an intraputamenal (IPA) multi-port catheter (1 .65 mm O.D.
diameter, 40 holes, 4 per 0.5 mm placed every 90°, 5 mm

length; Medtronic, Inc., Model #10532) and SynchroMed®

Statistical Methods
For the UPDRS endpoints, comparison of mean responses
across time was based on a linear mixed model with post hoc
20

pump (Medtronic, Inc., Model #8626L-18) contralateral to
the most affected side (see FIG. 1(a) and FIG. 1(b)). For each

obtained by the delta method and are based on a t-distribution

patient, a Leksell headframe was applied and a 1 mm slice

MRI scan was performed. Targeting of the catheter placement

with 9 degrees of freedom. For the CAPSIT-PD endpoints
25

some patients could not complete some tasks in which case a
score of 90 seconds was assigned to the Stand-Walk-Sit task
and 30 seconds was assigned to the Hand-Arm movement
test. Comparison of the distribution of responses was based

30

of means based on Fisher’s protected least signi?cant differ
ences procedure applied to the ranks across time determined
on a patient by patient basis. Control of the Type I error rate
for testing each week of follow-up to the baseline week was

was achieved using the Leksell Surgi Plan®(Copyright©
1991 -2003 Elekta Instruments AB Stockholm, Sweden). Fol
lowing standard stereotactic surgical procedures, the IPA
catheter was inserted into the medial putamen. The citrate

buffered saline-primed infusion pump was implanted subcu

on Friedman’s chi-square statistic with post hoc comparison

taneously in the ipsilateral lower quadrant abdominal wall
and a catheter was tunneled to connect the pump to the ind

welling IPA catheter. Locations of all catheters are schemati

cally shown in FIG. 1(a). A schematic of the infusion system
is seen in FIG. 1B. A postoperative MRI and posterior-ante
rior and lateral x-rays of the skull, chest and abdomen were
performed 24 hours after surgery to con?rm placement of the

35

obtained by applying the Bonferroni-Holm procedure (Holm,
S. A simple sequentially rejective multiple test procedure.
Scand. J. Statistics, 6: 65-70 (1979)). Statistical signi?cance
was determined at the 0.05 level.

catheter tip, continuity of the connections, and to detect puta
menal hemorrhage. All catheters were seen to be within the

putamen (see FIG. 1a).

comparison of means based on Fisher’s protected least sig
ni?cant differences procedure. Con?dence intervals for the
percent change from baseline to the 24 week follow-up were

40

Results
Testing was conducted in an operationally-de?ned OFF
condition: (i) anti-PD medications withheld for 2.5 times the

was stored in single-use vials in a buffer of 10 mM citrate and

duration of each drug’ s predicted serum half life, and (ii) prior
to the subject’s ?rst dose of medication on the day of testing.
Total UPDRS scores were signi?cantly improved by 16, 20
and 33% in the OFF condition at 8, 16, and 24 weeks, respec
tively (Table 3). Total UPDRS scores in the ON condition
were also improved by 26, 23, and 34% at 8, 16, and 24 weeks

150 mM sodium chloride (CBS) at pH 5.0. At implantation,

post-GDNF, respectively. ON testing was performed within

the pump was ?lled with preservative-free CBS and pro
grammed to infuse at 133 uL/day and pump re?lls occurred
monthly. The pump was programmed to infuse at a continu
ous basal infusion rate of 2 ul/hour. Small bolus injections

six hours after the subject’s ?rst dose of anti-PD medication
for the day. These improvements were maintained over the
?ve weeks after discontinuation of the highest-dose infusion

GDNF Treatment

The recombinant-methionyl human glial cell line-derived
neurotrophic factor (r-metHuGDNF) was prepared by
Amgen, Inc. (Thousand Oaks, Calif.). The r-metHuGDNF

45
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(30 mcg/ day). The 95% con?dence intervals (CI) for %
change from baseline at 24 weeks are given in Table 4, which
support the clinical signi?cance of the GDNF effects at 24
weeks. UPDRS (Part 111) Motor scores in OFF were also

(21.3 ul delivered in 117 seconds) were delivered every 6
hours to supplement the basal rate and to increase the brain
area affected by the drug. At the end of week four post sur
gery, r-metHuGDNF infusion began, with dose escalations at

55

signi?cantly improved by 13, 20, and 30% at 8, 16, and 24

60

weeks post-GDNF, respectively. UPDRS Motor scores in ON
were seen to be signi?cantly improved by 35, 30, and 30% at
8, 16, and 24 weeks post-GDNF, respectively. The 95% con
?dence intervals (CI) for % change from baseline at 24 weeks
are given in Table 4, which support the clinical signi?cance of

eight week intervals from 3 ug/day to 10 ug/day to 30 ug/day.
Solution concentrations of GDNF were adjusted to deliver the

same amount of ?uid (133 pl) per day. After 24 weeks of
infusion, the remaining r-metHuGDNF was removed from
the pump and the pump was ?lled with CBS. Due to the slow

drug infusion rate, and the length of catheter tubing between
the pump and the tip of the putamenal catheter, it takes

the GDNF effects at 24 weeks. UPDRS Motor scores

approximately one week for r-metHuGDNF in the tubing to
clear. Therefore, a total washout period of ?ve weeks was
needed to assess the effects of four weeks of trophic factor

out. In addition, eight patients showed improved postural

withdrawal. After the drug washout, patients had the option of
reinstating GDNF treatment at the highest previous tolerated

remained signi?cantly improved in OFF and ON after wash
stability in OFF, seven reported decreased end-of-dose ?uc
65

tuations and three experienced decreased dyskinesia (Table
2). Other motor/ sensory improvements included reduced
hypophonia (OFF and ON) in six patients, reduced hypo

US 8,946,151 B2
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mimia in eight patients and improved taste and smell reported
by one patient (Table 2). The observed reduction in bradyki

the site of intraputamenal infusion, with signi?cant improve

testing and were improved by 26% in OFF at six months
post-GDNF. Bilateral improvements were also evident in the
Arm-Hand test measuring movement speed between two

experienced by all ten subjects immediately following sur
gery and sporadically thereafter. All patients experienced
headaches the day following surgery, which resolved and did

ments ranging from 31-44% at 16 and 24 weeks post-GDNF.
nesia was supported by the CAPSIT-PD measures of timed
Safety and Side Effects
Hand-Arrn and SWS tests. The results of testing in the OFF
The unilateral pump implantation procedure was safe, with
and ON condition are seen in Table 3. Bilateral axial move- 5 few adverse events reported by all ten patients (Table 2).
ments including balance and gait were measured in SWS
There was general discomfort from the pump, which was

points 30 cm apart. Performance times of the Arm-Hand test 10 not reoccur. The MRI changes consisted of a halo of increased
were signi?cantly faster in both ON and OFF on both the
signal intensity on T2-weighted images less than 1 cm in
contralateral and ipsilateral sides to
thickness around the catheter. There was no change in body

TABLE 3
GDNF Improves UPDRS and CAPSIT Measures
8 WEEKS

Tests

BASELINE

Total UPDRS
Motor
UPDRS
CAPSIT
Stand, Walk,

z
z
z
z
z

P*

3 ug/day
z
z
z
z
z
z

P+

OFF
ON
OFF
ON
OFF
ON

64
47
40
23
39
22

5
3
4
2
8
5

<.0001
0.0005
0.0004
0.0201
0.0464
0.1032

54
35
35
15
37
19

4 (-16%)
3 (-26%)
3 (-13%)
3 (-35%)
10 (-5%)
3 (-14%)

0.011
0.0011
0.0291
0.0075
0.1741
-

OFF
ON

18 z 2
13 r 2

0.0002
0.0004

15 z 3 (-17%)
12 r 2 (—8%)

0.0792
0.2680

OFF
ON

15 z 2
12 z 2

0.0005
0.0005

12 z 1 (-20%)
10 z 1 (-17%)

0.0348
0.0242

Sit
CAPSIT
Contralateral

Hand/Arm
CAPSIT
Ipsilateral

Hand/Arm
16 WEEKS

Tests

24 WEEKS

10 ug/day

Total UPDRS

z
z
z
z
z

4
5
3
4
7

P++

(-20%)
(-23%)
(-20%)
(-30%)
(-26%)

0.0014
0.023
0.0034
0.0166
0.0491

30 ug/day
z5
z4
z4
z4
z9

(-33%)
(-34%)
(-30%)
(-30%)
(-26%)

<0.0001
<0.0001
<0.0001
0.0090
0.0012

Motor
UPDRS
CAPSIT

51
36
32
16
29

Stand, Walk,

ON

15 z 1 (-32%)

OFF
ON

12 z 2 (-43%)
9 z 1 (-31%)

0.0037 10 z 2 (-44%)
<.0001 8 z 2 (-38%)

<.0001 14 z 3 (-22%)
<0.0001 10 z 2 (-23%)

0.0009
0.0010

OFF
ON

10 z 1 (-33%)
8 z 1 (-33%)

<.0001
<.0001

<0.0001 11 z 1 (-27%)
<0.0001 8 z 1 (-33%)

0.0004
<.0001

14 z 1 (-36%)

-

53
34
33
14
31

:4
z4
z3
z3
z8

(-19%)
(-30%)
(-18%)
(-39%)
(-21%)

P++++

OFF
ON
OFF
ON
OFF

-

43
31
28
16
29

P+++ WASHOUT

14 z 1 (-32%)

0.0037
0.0004
0.0038
0.0027
0.0491
-

Sit
CAPSIT

Contra—lateral
Hand/Arm
CAPSIT
Ipsilateral
Hand/Arm

9 z 1 (-40%)
8 z 1 (-33%)

Baseline UPDRS scores for each patient are the means ofthree pre-GDNF determinations at —1, +1 and + 4 weeks following

catheter implantation.
UPDRS measures are means i SEM.

CAPSIT measures are in seconds i SEM.

*P value for comparing response across time.

P values for post hoc comparisons:
+ 8 weeks vs. baseline;
++ 16 weeks vs. baseline;
+++ 24 weeks vs. baseline;
++++ washout vs. baseline

weight during the trial.Adverse event frequencies were: cath

TABLE 4

eter re-placement (1/ 10), infection (0/ 10), pump failure
55

95% Con?dence intervals after 24 weeks of GDNF therapy
95% Cl

Endpoint

State

% Improvement

Low

High

Total UPDRS
Total UPDRS
Motor UPDRS
Motor UPDRS

011
On
Off
On

33%
34%
30%
30%

18%
l 6%
15%
5%

47%
51%
48%
61%

(0/ 10). Two subjects reported transient Lhermitte’s symp
toms on 1-2 occasions. None of the subjects reported nausea,
anorexia, vomiting or weight change as was seen by Nutt, et
60

65

Con?dence intervals for percent change from baseline to
improvement in Table 4 at 24 weeks.

(0/ 10), hemorrhage (0/ 10), blood chemistry abnormalities
(0/ 10) and delivery system complications/disconnections

al., (2003). In addition, none of our ten subjects experienced
hyponatraemia or alterations in antidiuretic hormone (ADH).
The sustained improvements in all ten subjects are consis
tent with extensive preclinical data suggesting GDNF e?i
cacy in treating PD. The 95% con?dence limits for the total
and motor UPDRS scores in ON and OFF further support the
clinical signi?cance of the results. Decreases over baseline in
the total and motor UPDRS scores after one-month washout

US 8,946,151 B2
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indicate that the positive effects of GDNF may persist for at
least four weeks after GDNF withdrawal. However, these

teria included women of child-bearing age, age over 65, the

presence of clinically signi?cant depression, or systemic dis

persistent gains may be less in magnitude compared to the

ease or inability or unwillingness to comply with long-term

maximum bene?t observed during active GDNF infusion.
This is consistent with prior studies in animal models of PD

follow-up.
Surgery

(Grondin, R., et al., (2002); Grondin, R., et al., (2003),
Hebert, M. A., (1997)).

Sub cortical nuclei were localized and targeted using high
resolution MR images acquired under strict stereotactic con
ditions. Under general anesthesia, a modi?ed Leksell stereo
tactic frame was a?ixed parallel to the orbito-meatal plane.
The anterior (AC) and posterior (PC) commisures were iden
ti?ed in a mid-sagittal planning scan. Axial images 2 mm
thick were acquired parallel to the AC-PC plane and coronal

Sustained and consistent placebo effects do not typically
occur in PD subjects (14,15) and patients with PD do not
spontaneously improve over time making these confounds
less likely explanations for the time course of improvements
we observed. Strikingly, signi?cant effects were observed in

all subjects receiving intraputamenal infusion of GDNF. Such

images orthogonal to these then obtained. Using magni?ed

consistent effects have not been seen in other treatments for

hard copies of the MRI scans the inversion recovery scans
were overlaid with the inverted T2 images to enhance the

PD such as DBS or fetal cell transplants (Krack, P., et al.,

de?nition of the putamenal boundaries in both planes. Using

Five-year follow-up of bilateral stimulation of the subtha
lamic nucleus in advanced Parkinson’s disease, N. Engl. J.
Med., 349: 1925-1 934 (2003); Olanow, C. W., et al., A double
blind controlled trial of bilateral fetal nigral transplantation in

Parkinson’s disease,Ann. Neurol. 54:403-414 (2003)). Eight
subjects in this study showed improved postural stability, six
of the ten patients had improved speech (reduced hypopho

the PET images, the area of the postero-dorsal putamen with

the lowest 18F-dopa uptake was targeted for infusion; stereo
tactic target coordinates were recorded and a trajectory
20

general anesthesia. Under stereotactic conditions, 1 mm
diameter guide tubes were implanted to a point above the
putamen target over a guide rod. A 0.6 mm guide wire was

nia) and seven patients exhibited decreased hypomimia. The
quality of ON time was improved by decreased symptom
?uctuations in seven subjects. While dyskinesias were not

planned. The following day, surgery was performed under

introduced down the guide tube to target, following which the
25

patients underwent repeat MR/CT imaging to verify target

prominent in this patient group, they were reduced in three
subjects. All of the patients also reported an increased sense

localization. The guide wire was then replaced with a 0.6 mm
diameter catheter introduced to target. r-metHuGDNF

of well-being (manuscript in preparation), suggesting an

primed SynchroMed pumps (Medtronic Inc, Minneapolis)
were implanted in the upper abdominal region, subcutane

additional effect of intraputamenal GDNF.
30

Example 2
Treatment of Parkinson’s Disease in Humans with
Convection-Enhanced Infusion of GDNF into the
Putamen

cosmetic appearance. Catheters were tunneled connecting the
pumps to the indwelling 0.6 mm intraparenchymal brain cath
35 eters.

Convection-enhanced infusion into the targeted brain tis
sue was achieved in this study by pumping drug at a relatively

Study Design
Five patients with idiopathic, L-dopa responsive PD who
were poorly controlled on optimal medical therapy were

identi?ed. The ?rst patient (P1) had predominantly unilateral
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disease affecting the left side and underwent contralateral
putamenal implantation of catheter and pump for r-metH

uGDNF delivery. The remaining patients (P2-5) had bilateral
disease and bilateral putamenal implantations of delivery sys
tems. The precise region of the dorsal putamen to be targeted
for infusion was determined by co-localization studies using
1 8F-dopa PET and MR images. Under MRI guidance, single
port catheters were placed into the dorsal putamen, the site of

45

reduce the resistance outside the catheter, therefore reducing
the pressure gradient and bulk ?ow into the tissue substan

tially. Additionally, the smallest possible catheter is preferred
since catheter placement would be expected to cause tissue
trauma and local necrosis resistance to ?ow would be lower
along the catheter tract. Therefore, it follows that a smaller
50

complications. P1 required perioperative repositioning of the
catheter to center exactly within the dorsal putamen. This was
achieved successfully on a second pass during the surgical

procedure. In addition, patient 4 developed a wound infection

high rate through the smallest possible catheter having a
single port at its distal end. Otherwise, drug emerging from a
single port in the distal end would tend to travel up the path of
least resistance, i.e., up the catheter/tissue interface. Because
the ?ow up this space is proportional to the radius squared,
even small increases in catheter size would be expected to

maximal loss of 18F-?uorodopa signal (con?rmed by PET in
all subjects). Pump placement and stereotactic surgery were
tolerated well by all patients. However, there were some

ously in the ?rst patient, and subfascially (beneath the ante
rior rectus sheath) in the subsequent cases; subfascial place
ment reduced the pump pro?le in the abdomen and improved
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related to the pumps and connection tubing that was success

catheter would result in less tissue damage and less drug
?owing back along the catheter tissue interface to the cortex
and entering the CSF space. On the other hand, with larger
catheters and slower infusion rates, ?uid penetration into the
tissues becomes solely dependent upon diffusion down a
concentration gradient, which due to the size of the GDNF
molecule will be very limited. This is supported by Chen et al.

fully treated with explantation of the extracranial devices,

(J. Neurosurg 90:315-320, 1999isee appendix), who dem

antibiotics and re-implantation within 4 weeks.
Patients
Five PD patients were included in this pilot study. Ethical
approval was obtained from the local ethics committees both
at Frenchay Hospital and the Hammersmith Hospitals Trusts
and all participants signed full consent forms. All patients
were diagnosed as suffering from idiopathic PD according to
standard criteria (brain bank criteria). Patients were selected
for surgery when they were suffering signi?cant functional

onstrate in a rat model that infusing protein into the striatum
with a 0.4 mm catheter results in 5% loss of infusate through

impairment despite optimal medical therapy. Exclusion cri
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leak back along the catheter, and by increasing the diameter to
0.6 mm, the loss increases to 35%. In this study, increasing the
infusion rate beyond about 6 ul per hour, increased leak back

65

and loss of infusate and infusate concentration had no effect
on the volume of distribution.
r-metHuGDNF Production and Infusion

Recombinant-methionyl human glial cell line-derived neu

rotrophic factor (r-metHuGDNF) was prepared by Amgen
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Inc. This protein was produced in Escherichia coli cells that
contain an expression plasmid with a DNA insert encoding

logical assessment. All ?ve patients were assessed at 12 and

24 months post implantation. The signi?cance of changes in
cognitive test performance was evaluated using con?dence

mature human GDNF, with an addition of an amino terminal

methionine. r-metHuGDNF is liquid formulated with 10 mM
sodium citrate and 150 mM sodium chloride at a pH of 5.0. It
was supplied in single-use vials at a concentration of 10

intervals derived from the standard error of prediction around
the predicted true score at baseline (Lord, F. M. and Novick,
M. R. Statistical theories of mental test scores. Reading,

mg/mL. Following implantation, the SynchroMed pumps

Mass.: Addison-Wesley, (1968); Atkinson, L. Three standard

were programmed to deliver a continuous infusion of 14.4 pg

errors of measurement and the Wechsler Memory Scalei

of r-metHuGDNF per putamen per day at rate of 6 pl per hour.
The pumps were re?lled monthly with fresh solution. The low

Revised. Psychological Assessment: A journal of consulting
and clinical psychology, 3: 136-138 (1991)). A signi?cant

concentration of r-metHuGDNF was maintained for a period
of 8 weeks. At 2 months the pumps were re?lled with fresh

change was inferred if a score at either 12 or 24 months fell

solution of higher concentration and programmed to deliver

unilateral case the baseline score was at 12 months and

43.2 pg of r-metHuGDNF per putamen per day at a rate of 6

at regular intervals. Between 12 and 18 months, all patients

change scores were inferred for performance at 24 months).
In addition, a PD control group consisting of 18 patients who
had undergone other forms of surgery for PD was used to
establish the effect of repeat cognitive assessment over a 12
month period. For each patient in this group two postopera
tive neuropsychological assessments were available. This
control group was comparable with the GDNF patient group
in terms of years of education, age at surgery, duration of PD
at surgery and NART estimated FSIQ (p>0.05).

received a continuous infusion of 14.4 pg of r-metHuGDNF

Scanning Procedures and Image Analysis

outside of the con?dence interval of the baseline score (for the

pl per hour. Providing good tolerance and no side effects, this
dose was to be maintained for the duration of the trial. How

ever, due to the development of high-signal MRI changes of
uncertain signi?cance, the infusion parameters were altered
to deliver lower doses (10.8-14.4 pg of r-metHuGDNF) at
lower rates (2-6 pl per hour), in attempt to establish safe and

20

clinically effective parameters, with repeat MRI monitoring
per putamen per day at rate of 6 pl per hour. At 18 months the
dose of GDNF was increased to 28.8 pg per putamen per day

25

at rate of 6 pl per hour, and remained so until 24 months or
longer except in P4 who reverted back to 14.4 pg at 20
months.

Clinical Evaluation and Follow-Up
Clinical evaluations were based on the Core Assessment 30

Program for lntracerebral Transplantations (CAPIT)(Lang
ston, J. W. et al., Core assessment program for intracerebral

35

ments were performed in both off and on medication states.

Before they were assessed off medication, patients fasted and
40

ments were then repeated after administration of L-dopa
when the patients were “on”.
Health-Related Quality of Life Outcome Measurement and

(1990b); Pate et al., Correlation of striatal ?uorodopa uptake
in the MPTP monkey with dopaminergic indices. Annals of
Neurology, 34: 331-338 (1993) and the UPDRS off medica
tion (Morrish, et al., Measuring the rate of progression and
estimating the preclinical period of Parkinson’s disease with

[18F]dopa PET. Journal ofNeurology, Neurosurgery & Psy
chiatry, 64: 314-319 (1998)), in particular, with the bradyki

Follow-Up
Patients were also assessed using validated quality of life

Brooks et al., Differing patterns of striatal l 8F-dopa uptake in
Parkinson’s disease, multiple system atrophy, and progres

sive supranuclear palsy. Annals of Neurology, 28:547-555

son’s Disease Rating Scale (UPDRS) and underwent timed
motor tests at baseline, 3, 6, 12, 18 and 24 months. Assess
medications were withdrawn overnight. The same assess

marker of dopamine storage and the functional integrity of
dopamine terminals. Previous human and animal lesion stud
ies have demonstrated that striatal 18F-dopa PET correlates
with nigral cell numbers, dopamine content in striatal termi
nals (Garnett, et al., Dopamine visualized in the basal ganglia
of living man, Nature, 305:137-138 (1983); Martin et al.,
Nigrostriatal function in humans studied with positron emis

sion tomography. Annals ofNeurology, 26:535-542 (1989);

transplantations (CAPIT). Mov Disord., 7, 2-13 (1992)) a
validated protocol for evaluating surgical treatments of idio
pathic PD. All patients were evaluated on the Uni?ed Parkin

18F-dopa PET provides a measure of synaptic amino acid
decarboxylase (AADC) activity and hence acts as an in vivo
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questionnaires: the 39-item Parkinson’s Disease Question
naire (PDQ 39) and the 36-item Medical Outcomes Study

nesia and rigidity sub scores (Otsuka, et al., Differences in the
reduced 18F-Dopa uptakes of the caudate and the putamen in
Parkinson’s disease: correlations with the three main symp

made using Student’s paired-samples ttest.

toms, Journal of the Neurological Sciences, 136: 169-173
(1996)). Furthermore, it is possible to demonstrate progres
sive decline of striatal 18F-dopa uptake in patients with PD
over time (Morrish, et al., 1998; Morrish, et al., An [18F]
dopa-PET and clinical study of the rate of progression in
Parkinson’s disease. Brain, 119 (Pt 2), 585-591 (1996)). 18F

Neuropsychological Evaluation and Follow-Up

dopa PET was used here to assess striatal dopamine terminal

short form health survey (SF-36) were used before surgery

and after 3, 6, 12, 18, and 24 months. Descriptive statistics
(mean, standard deviation, range, 95% con?dence interval)
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were obtained for each variable. Comparisons over time were

function in ?ve PD patients receiving chronic intra-striatal

Also evaluated were changes in medication (L-dopa

equivalents) requirement and neuropsychology, which con

55

GDNF infusions.

tained tests of verbal intellect, verbal and visual memory,

The patients had 18F-dopa PET pre-operatively, and at 6,

attention, executive function, anxiety and depression as has
been previously described (McCarter, R. 1., et al., Cognitive
functioning after subthalamic nucleotomy for refractory Par
kinson’s disease. J. Neurol. Neurosurg. Psychiatry, 69: 60-66
(2000)). The battery of cognitive tests used was designed to
minimize the possible confounding effects of both slowness

12, 18, and 24 months postoperatively using an ECAT
EXACT HR++ camera (CTl/ Siemens 966; Knoxville, Term.)
in 3D acquisition mode following withdrawal from medica

of movement and movement dif?culty on cognitive test
results. Friedman’s Related Samples test was used to evaluate
the signi?cance of change over time in the rating scores. All

60

tion for at least 12 hours. Patients received 150 mg of carbi

dopa and 400 mg of entacapone; 1 hour later 111 MBq of
l 8F-dopa in normal saline was administered as an intravenous

65

bolus at the start of scanning. The images were acquired in 3D
mode as 26 time frames over 94.5 minutes (1><30 seconds,
4><1 min, 3><2 min, 3><3 min and 15x5 mins). Parametric

analyses were performed in SPSS. Four of the patients (all of

images of 18F-dopa in?ux constants (Ki) were generated from

the bilateral cases) underwent pre-operative neuropsycho

time frames 25 .5 to 94.5 minutes post injection using in house
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software based on the MTGA approach of Patlak and Blas

mittent, non-di stressing; and mo st frequently occurred at the
higher dose; and in fact it was often described as “pleasur
able”.
In all patients, T2 MR images showed a region of high

berg (Brooks, D. 1., The relationship between locomotor dis
ability, autonomic dysfunction, and the integrity of the striatal
dopaminergic system in patients with multiple system atro
phy, pure autonomic failure, and Parkinson’s disease, studied
with PET. Brain, 113 (Pt 5) 1539-1552 (1990a); Rakshi, J. S.
et al., Frontal, midbrain and striatal dopaminergic function in
early and advanced Parkinson’s disease A 3D [(18)F]dopa
PET study. Brain, 122 (Pt 9): 1637-1650 (1999); Patlak, C. S.
& Blasberg, R. G., Graphical evaluation of blood-to-brain
transfer constants from multiple-time uptake data. Generali

signal intensity around the tips of the catheters. This response
varied between patients, and even between the two hemi

spheres in bilaterally implanted cases. The signal change was
mo st evident following the dose escalation of r-metHuGDNF.
Uncertainty as to the relevance of these changes, led to a

reduction of r-metHuGDNF delivery back to 14.4 ug/puta
men/ day for all patients between 3 and 6 months that resulted
in a substantial reduction of the high signal.
Ef?cacy of r-metHuGDNF Infusion

zations. J. Cereb. Blood Flow Melab., 5: 584-590 (1985)).
Occipital counts from the same time frames were used to

generate the tissue reference input function. Integrated
images (time frames 25.5-94.5) were used to identify the
parameters required to transform the Ki images into standard

Improvement in patients’ parkinsonian symptoms and
signs were evident within 3 months of commencing the infu

stereotaxic MNI space. The transformation matrix was then

sion and continued to improve throughout the study. Patient

applied to the Ki images. After normalization a gaussian ?lter
(6x6><6 mm) was applied. Mean voxel values of the normal
ized Ki images were compared throughout the midbrain and
basal ganglia at baseline, 6, and 12 months postoperatively
using a paired Student’s t-test in SPM99 after application of

diaries revealed that periods of severe immobility, one of the
20

a mask to eliminate cortical signals and so reduce the number

of statistical comparisons.Any regional increases in l 8F-dopa
uptake could subsequently be de?ned as a volume of interest
and the mean Ki values for those volumes extracted using the

appropriate SPM tool (Brett, M., et al., Region of interest
analysis using an SPM toolbox, Neurolmage, 16 (2002)).
The integrated images were subsequently co-registered to
each patient’s MRI scan for region of interest (ROI) analysis.

25

increases in medication. The study protocol aimed to main
tain medication unchanged throughout the ?rst year of
r-metHuGDNF treatment. However, P3 had been taking
30

to L-dopa after GDNF infusion and also needed to reduce his
35

dosage. The other 3 patients needed slight increases in their
L-dopa equivalents intake. At 24 months, the mean daily dose
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mula as designated by Pahwa, et al. (Pahwa, R., et al., High
frequency stimulation of the globus pallidus for the treatment
ofParkinson’s disease, Neurology, 49: 249-253 (1997)).
The most widely used and validated scale for assessing

of L-dopa equivalents was reduced by 26% (based on a for

posterior halves. The position of the catheter tip was also
calculated relative to the AC-PC line and an oval region of

functional changes in PD is the Uni?ed Parkinson’s Disease

Rating Scale (UPDRS). In all patients, the rate of symptom
atic improvement was maximal in the ?rst 3 months of GDNF
infusion and, thereafter, there was slower but sustained

18F activity on the parametric image. In the 4 patients oper
ated on bilaterally, the mean Ki values for the left and right
regions of interest were averaged to produce one Ki value for
each of the ?ve ROIs per scan. Only the ROIs from the
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r-metHuGDNF infusion showed a reduction from baseline of
48%. Although this was a small group of patients, we per

surgery were included in the analyses. The patient’s Ki values
50

Lack of Adverse Effects of r-metHuGDNF Infusion
Surprisingly, side effects due to r-metHuGDNF infusion

points (P<0.005; Friedman test). The largest effects were seen
over the ?rst three months, but the effect persisted throughout

iting or weight loss reported as in the previous intraventricu

the trial. There was also a 45% reduction in total UPDRS
55

tological or blood chemistry abnormalities. At the high dose

scores in the clinically de?ned “on” phase by 12 months,
which followed a similar pattern over time (P<0.002; Fried
man test). Although P4’s ?nal score was still below baseline,
he did show a worsening of symptoms at the twelve-month
assessment; this may have been due to an unrelated inter

(43.2 ug/putamen/day), 3 subjects reported abnormalities of
taste and smell (soapy or metallic), 2 subjects reported that
their dreams had become abnormally vivid, and 4 subjects
described a Lhermitte’s phenomenon (tingling passing from

formed a non-parametric signi?cance test, which showed that
this reduction was highly signi?cant across the three time

itself were very limited. There was no nausea, anorexia, vom

lar trial (Kordower, J. H. et al., 1999). There were no haema

improvement throughout the entire 24 months of follow-up.
The total UPDRS scores in the clinically de?ned “off” phase
when assessed 12 months following commencement of

operated right side of the patient who received unilateral
were then subjected to a paired Student’s two-tailed t test.

medication on demand due to frequent periods of akinesia at
the onset of the study, and needed to reduce his medication as

his symptoms improved. Patient P5 had increased sensitivity

plane. The subsequent transformation matrix was then
applied to individual Ki images in order to transform them
into the individual MRI space. Regions of interest (ROIs)

interest (6 mm><12 mm) centred at the tip location in the axial
plane. The ROI was then copied onto 2 planes either side of
the slice containing the calculated tip location, creating a 12
mm><6 mm><5 mm (0.36 cc) volume of interest centered on the
catheter tip. The regions of interest were then used to sample

in P4, who additionally reported short-lived infrequent early
morning occurrences. These changes were not due to

All MRIs had been previously reformatted in the AC-PC

were traced on the MRI and included the head of the caudate
and the dorsal putamen which was divided into anterior and

cardinal features of PD that occupied approximately 20% of
the waking day prior to surgery, were eliminated completely
by 6 months of r-metHuGDNF infusion. At 24-months dys
kinesias were reduced signi?cantly by 73% in duration
(p<0.05) and were all reported as mild in nature (Table 4). We
observed mild dyskinesias in the practically de?ned off state
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current infection.

the neck down through the arms and sometimes onto the trunk

The patients experienced a mean 41% (p<0.001) improve

and down the legs provoked by neck ?exion). None of these

ment in ‘off-period’ total UPDRS over the ?rst 12 months of
follow-up. When the results were broken down, it was clear
that these effects in total UPDRS during the “off” phase were

effects necessitated immediate dose cessation or reduction,

and all remitted (except for occasional, mild Lhermitte’s
sign) after the dose change discussed below that was insti
tuted after the appearance of a high-density signal on MRI

re?ected by improvements in both activities of daily living
(ADL) UPDRS subscale II (P<0.002; Friedman test) and

(end of month 3). The Lhermitte’s events were mild, inter

motor UPDRS subscale III scores (P<0.002; Friedman test).
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